0002066836 2025-11-01 2026-07-31 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2025-01-31 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2024-12-01 2025-01-31 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2025-05-31 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2025-05-01 2025-05-31 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2024-11-01 2025-10-31 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2025-10-23 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2025-10-28 2025-10-28 0002066836 cnxu:EntityRelatedToBoardOfDirectorsMember cnxu:NonBrokeredPrivatePlacementsMember 2025-10-28 2025-10-28 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2025-11-12 2025-11-12 0002066836 cnxu:EntityRelatedToBoardOfDirectorsMember cnxu:NonBrokeredPrivatePlacementsMember 2025-11-12 2025-11-12 0002066836 cnxu:EntityRelatedToBoardOfDirectorsMember cnxu:NonBrokeredPrivatePlacementsMember 2025-11-12 0002066836 cnxu:EntityRelatedToBoardOfDirectorsMember cnxu:NonBrokeredPrivatePlacementsMember 2026-01-26 2026-01-26 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2026-01-20 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2026-03-23 2026-03-23 0002066836 cnxu:NonBrokeredPrivatePlacementsMember 2026-03-23 0002066836 cnxu:BrokeredPrivatePlacementsMember 2025-07-31 0002066836 cnxu:BrokeredPrivatePlacementsMember 2025-09-02 2025-09-02 0002066836 cnxu:BrokeredPrivatePlacementsMember 2025-09-18 2025-09-18 0002066836 cnxu:BrokeredPrivatePlacementsMember 2025-10-07 2025-10-07 0002066836 cnxu:BrokeredPrivatePlacementsMember 2025-08-01 2025-10-07 0002066836 cnxu:BrokerMember cnxu:BrokeredPrivatePlacementsMember 2025-08-01 2025-10-07 0002066836 cnxu:ConsultantMember cnxu:AdvisoryAndConsultancyServicesMember 2025-05-08 0002066836 cnxu:ConsultantMember cnxu:AdvisoryAndConsultancyServicesMember 2025-10-31 0002066836 cnxu:ConsultantMember cnxu:AdvisoryAndConsultancyServicesMember 2025-05-08 2025-05-08 0002066836 cnxu:ConsultantMember cnxu:AdvisoryAndConsultancyServicesMember 2026-05-01 2026-07-31 0002066836 us-gaap:RestrictedStockUnitsRSUMember 2025-06-27 2025-06-27 0002066836 srt:DirectorMember 2025-01-01 2025-01-15 0002066836 cnxu:ConsultantMember 2025-05-01 2025-05-31 0002066836 cnxu:ConsultantMember 2025-10-31 0002066836 cnxu:ConsultantMember 2026-05-01 2026-07-31 0002066836 cnxu:ConsultantMember 2025-11-01 2026-07-31 0002066836 cnxu:EmployeesAndDirectorMember 2025-10-01 2025-10-15 0002066836 cnxu:DirectorInSettlementOfFeesMember 2026-03-17 2026-03-17 0002066836 cnxu:DirectorInSettlementOfFeesMember 2026-03-17 0002066836 2024-11-30 2025-01-31 0002066836 srt:DirectorMember 2025-01-21 2025-01-21 0002066836 srt:DirectorMember 2025-05-01 2025-07-31 0002066836 srt:DirectorMember 2024-11-01 2025-07-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneThreeMember 2025-06-01 2025-06-05 0002066836 cnxu:ConsultantMember cnxu:ConsultingAgreementFor24MonthMember 2025-05-01 2025-05-31 0002066836 cnxu:ConsultantMember cnxu:ConsultingAgreementFor24MonthMember 2025-10-31 0002066836 cnxu:ConsultantMember cnxu:ConsultingAgreementFor24MonthMember 2026-05-01 2026-07-31 0002066836 cnxu:ConsultantMember cnxu:ConsultingAgreementFor24MonthMember 2025-11-01 2026-07-31 0002066836 srt:DirectorMember 2025-12-23 2025-12-23 0002066836 cnxu:WarrantExerciseIncentiveProgramMember 2025-10-01 2025-10-01 0002066836 cnxu:WarrantExerciseIncentiveProgramMember 2025-10-01 0002066836 cnxu:WarrantExerciseIncentiveProgramMember 2026-02-11 2026-02-11 0002066836 cnxu:StockIncentivePlanMember 2025-06-07 0002066836 cnxu:EmployeeMember 2025-11-01 2025-11-30 0002066836 cnxu:EmployeeMember 2026-05-01 2026-07-31 0002066836 cnxu:EmployeeMember 2025-11-01 2026-07-31 0002066836 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2026-07-31 0002066836 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2025-10-31 0002066836 srt:MinimumMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2025-10-31 0002066836 srt:MaximumMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2025-10-31 0002066836 srt:MinimumMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2024-11-01 2025-10-31 0002066836 srt:MaximumMember us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2024-11-01 2025-10-31 0002066836 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2025-11-01 2026-07-31 0002066836 srt:MinimumMember us-gaap:WarrantMember cnxu:CompensationMember 2025-10-31 0002066836 us-gaap:WarrantMember cnxu:CompensationMember 2026-07-31 0002066836 srt:MaximumMember us-gaap:WarrantMember cnxu:CompensationMember 2025-10-31 0002066836 us-gaap:WarrantMember cnxu:CompensationMember 2025-11-01 2026-07-31 0002066836 srt:MinimumMember us-gaap:WarrantMember cnxu:CompensationMember 2024-11-01 2025-10-31 0002066836 srt:MaximumMember us-gaap:WarrantMember cnxu:CompensationMember 2024-11-01 2025-10-31 0002066836 srt:MinimumMember us-gaap:WarrantMember cnxu:IncentiveProgramMember 2026-07-31 0002066836 us-gaap:WarrantMember cnxu:IncentiveProgramMember 2026-07-31 0002066836 us-gaap:WarrantMember cnxu:IncentiveProgramMember 2025-11-01 2026-07-31 0002066836 srt:MinimumMember us-gaap:WarrantMember cnxu:IncentiveProgramMember 2025-11-01 2026-07-31 0002066836 us-gaap:EmployeeStockOptionMember 2026-07-31 0002066836 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2025-10-31 0002066836 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2025-10-31 0002066836 us-gaap:EmployeeStockOptionMember 2025-11-01 2026-07-31 0002066836 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-11-01 2025-10-31 0002066836 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-11-01 2025-10-31 0002066836 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2025-11-01 2026-07-31 0002066836 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2025-11-01 2026-07-31 0002066836 us-gaap:WarrantMember 2024-10-31 0002066836 us-gaap:WarrantMember 2023-11-01 2024-10-31 0002066836 us-gaap:WarrantMember 2024-11-01 2025-10-31 0002066836 us-gaap:WarrantMember 2025-10-31 0002066836 us-gaap:WarrantMember 2025-11-01 2026-07-31 0002066836 us-gaap:WarrantMember 2026-07-31 0002066836 us-gaap:EmployeeStockOptionMember 2024-10-31 0002066836 us-gaap:EmployeeStockOptionMember 2024-11-01 2025-10-31 0002066836 us-gaap:EmployeeStockOptionMember 2025-10-31 0002066836 us-gaap:EmployeeStockOptionMember 2023-11-01 2024-10-31 0002066836 us-gaap:PrivatePlacementMember 2025-11-01 2026-07-31 0002066836 cnxu:CompensationMember 2025-11-01 2026-07-31 0002066836 cnxu:IncentiveProgramMember 2025-11-01 2026-07-31 0002066836 cnxu:ConsultantMember cnxu:AdvisoryAndConsultancyServicesMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorInSettlementOfFeesMember 2026-05-14 2026-05-14 0002066836 cnxu:DirectorInSettlementOfFeesMember 2026-05-14 0002066836 cnxu:VendorMember cnxu:MarketingAgreementOneMember 2026-05-01 2026-05-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementMember 2026-04-01 2026-04-28 0002066836 cnxu:VendorMember cnxu:MarketingAgreementMember 2026-05-01 2026-05-28 0002066836 cnxu:VendorMember cnxu:ServiceAgreementMember 2026-04-01 2026-04-28 0002066836 cnxu:VendorMember cnxu:MarketingAgreementOneMember 2026-05-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementOneMember 2025-11-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementTwoMember 2026-05-01 2026-05-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementTwoMember 2026-05-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementTwoMember 2025-11-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementThreeMember 2026-05-01 2026-05-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementThreeMember 2026-05-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementThreeMember 2025-11-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementFourMember 2026-05-01 2026-05-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementFourMember 2026-05-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementFourMember 2025-11-01 2026-07-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneOneMember 2024-11-01 2025-10-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneTwoMember 2026-05-01 2026-07-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneThreeMember 2026-05-01 2026-07-31 0002066836 srt:DirectorMember 2026-05-22 2026-05-22 0002066836 cnxu:FormerDirectorMember 2026-05-22 2026-05-22 0002066836 cnxu:ShareholderMember 2026-06-08 2026-06-08 0002066836 srt:DirectorMember 2026-06-18 2026-06-18 0002066836 cnxu:WarrantExerciseIncentiveProgramMember 2026-05-12 2026-05-12 0002066836 cnxu:WarrantExerciseIncentiveProgramMember 2026-06-05 2026-06-05 0002066836 cnxu:EntityRelatedToBoardOfDirectorsMember 2026-05-12 2026-05-12 0002066836 cnxu:WarrantExerciseIncentiveProgramMember 2026-06-18 2026-06-18 0002066836 srt:MaximumMember us-gaap:WarrantMember cnxu:IncentiveProgramMember 2026-07-31 0002066836 srt:MaximumMember us-gaap:WarrantMember cnxu:IncentiveProgramMember 2025-11-01 2026-07-31 0002066836 cnxu:ConsultantAndThreeAdvisorsMember 2026-02-09 2026-02-09 0002066836 cnxu:EachIndividualMember 2026-02-09 2026-02-09 0002066836 cnxu:ConsultantAndThreeAdvisorsMember 2026-05-01 2026-07-31 0002066836 cnxu:ConsultantAndThreeAdvisorsMember 2025-11-01 2026-07-31 0002066836 cnxu:ConsultantMember cnxu:AdvisoryAndConsultancyServicesMember 2025-05-01 2025-07-31 0002066836 cnxu:ConsultantMember cnxu:AdvisoryAndConsultancyServicesMember 2024-11-01 2025-07-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneFourMember 2026-05-01 2026-07-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneFourMember 2025-11-01 2026-07-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneFourMember 2025-05-01 2025-07-31 0002066836 cnxu:ThreeDirectorsMember cnxu:MilestoneFourMember 2024-11-01 2025-07-31 0002066836 cnxu:ConsultantMember 2024-11-01 2025-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementMember 2026-06-01 2026-06-28 0002066836 cnxu:VendorMember cnxu:MarketingAgreementMember 2026-07-01 2026-07-28 0002066836 cnxu:VendorMember cnxu:MarketingAgreementMember 2026-05-01 2026-07-31 0002066836 cnxu:VendorMember cnxu:MarketingAgreementMember 2025-11-01 2026-07-31 0002066836 cnxu:EmployeesAndDirectorMember 2026-05-14 2026-05-14 0002066836 cnxu:VendorMember cnxu:MarketingAgreementOneMember 2026-05-01 2026-05-22 0002066836 cnxu:VendorMember cnxu:MarketingAgreementOneMember 2026-06-01 2026-06-22 0002066836 cnxu:VendorMember cnxu:MarketingAgreementOneMember 2026-07-01 2026-07-22 0002066836 cnxu:VendorMember cnxu:MarketingAgreementTwoMember 2026-06-01 2026-06-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementTwoMember 2026-07-01 2026-07-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementThreeMember 2026-06-01 2026-06-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementThreeMember 2026-07-01 2026-07-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementFourMember 2026-07-01 2026-07-21 0002066836 cnxu:VendorMember cnxu:MarketingAgreementFourMember 2026-06-01 2026-06-21 0002066836 cnxu:ConsultantMember cnxu:ConsultingAgreementFor24MonthMember 2025-05-01 2025-07-31 0002066836 cnxu:ConsultantMember cnxu:ConsultingAgreementFor24MonthMember 2024-11-01 2025-07-31 0002066836 us-gaap:PatentsMember 2023-11-20 2023-11-20 0002066836 us-gaap:PatentsMember 2026-07-31 0002066836 us-gaap:PatentsMember 2025-10-31 0002066836 us-gaap:PatentsMember 2025-11-01 2026-07-31 0002066836 us-gaap:PatentsMember 2024-11-01 2025-07-31 0002066836 us-gaap:PatentsMember 2026-05-01 2026-07-31 0002066836 us-gaap:PatentsMember 2025-05-01 2025-07-31 0002066836 2026-07-31 0002066836 2025-10-31 0002066836 cnxu:SeriesSeedPreferredStockMember 2026-07-31 0002066836 2026-05-01 2026-07-31 0002066836 2025-05-01 2025-07-31 0002066836 2024-11-01 2025-07-31 0002066836 2024-12-01 2024-12-30 0002066836 2024-12-31 0002066836 2025-06-05 0002066836 2025-07-31 0002066836 2025-07-01 2025-07-31 0002066836 us-gaap:PrivatePlacementMember 2025-10-01 2025-10-28 0002066836 us-gaap:PrivatePlacementMember 2025-10-28 0002066836 us-gaap:PrivatePlacementMember 2026-03-01 2026-03-23 0002066836 us-gaap:PrivatePlacementMember 2026-03-23 0002066836 us-gaap:WarrantMember 2025-11-01 2026-07-31 0002066836 us-gaap:WarrantMember 2024-11-01 2025-07-31 0002066836 us-gaap:StockOptionMember 2025-11-01 2026-07-31 0002066836 us-gaap:StockOptionMember 2024-11-01 2025-07-31 0002066836 us-gaap:EquipmentMember 2026-07-31 0002066836 cnxu:LabEquipmentMember 2026-07-31 0002066836 us-gaap:FurnitureAndFixturesMember 2026-07-31 0002066836 us-gaap:ComputerEquipmentMember 2026-07-31 0002066836 2024-01-01 2024-12-31 0002066836 us-gaap:RestrictedStockUnitsRSUMember 2024-11-01 2025-07-31 0002066836 us-gaap:RestrictedStockUnitsRSUMember 2025-11-01 2026-07-31 0002066836 us-gaap:SubsequentEventMember 2026-08-01 2026-08-18 0002066836 us-gaap:PreferredStockMember 2025-10-31 0002066836 us-gaap:CommonStockMember 2025-10-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2025-10-31 0002066836 us-gaap:RetainedEarningsMember 2025-10-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2025-11-01 2026-07-31 0002066836 us-gaap:CommonStockMember 2025-11-01 2026-07-31 0002066836 us-gaap:RetainedEarningsMember 2026-07-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2026-07-31 0002066836 us-gaap:CommonStockMember 2026-07-31 0002066836 us-gaap:PreferredStockMember 2026-07-31 0002066836 2026-04-30 0002066836 us-gaap:RetainedEarningsMember 2026-04-30 0002066836 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0002066836 us-gaap:CommonStockMember 2026-04-30 0002066836 us-gaap:PreferredStockMember 2026-04-30 0002066836 2024-10-31 0002066836 us-gaap:RetainedEarningsMember 2024-10-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0002066836 us-gaap:CommonStockMember 2024-10-31 0002066836 us-gaap:PreferredStockMember 2024-10-31 0002066836 us-gaap:RetainedEarningsMember 2025-07-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2025-07-31 0002066836 us-gaap:CommonStockMember 2025-07-31 0002066836 us-gaap:PreferredStockMember 2025-07-31 0002066836 us-gaap:CommonStockMember 2025-05-01 2025-07-31 0002066836 us-gaap:CommonStockMember 2026-05-01 2026-07-31 0002066836 us-gaap:CommonStockMember 2024-11-01 2025-07-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-07-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2025-05-01 2025-07-31 0002066836 us-gaap:RetainedEarningsMember 2025-05-01 2025-07-31 0002066836 us-gaap:RetainedEarningsMember 2026-05-01 2026-07-31 0002066836 us-gaap:AdditionalPaidInCapitalMember 2026-05-01 2026-07-31 0002066836 us-gaap:RetainedEarningsMember 2025-11-01 2026-07-31 0002066836 2025-04-30 0002066836 us-gaap:RetainedEarningsMember 2025-04-30 0002066836 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0002066836 us-gaap:CommonStockMember 2025-04-30 0002066836 us-gaap:PreferredStockMember 2025-04-30 0002066836 us-gaap:RetainedEarningsMember 2024-11-01 2025-07-31 0002066836 us-gaap:FurnitureAndFixturesMember 2025-10-31 0002066836 us-gaap:EquipmentMember 2025-10-31 0002066836 us-gaap:ComputerEquipmentMember 2025-10-31 0002066836 cnxu:TargetCompanyMember 2025-05-14 0002066836 cnxu:TargetCompanyMember 2025-05-01 2025-05-14 0002066836 cnxu:TargetCompanyMember 2025-10-31 0002066836 cnxu:TargetCompanyMember 2026-03-01 2026-03-24 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-24 2026-08-24 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-24 0002066836 us-gaap:SubsequentEventMember 2026-08-21 2026-08-21 0002066836 us-gaap:ServiceAgreementsMember 2026-07-12 2026-07-12 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-09-01 2026-09-01 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-28 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-28 2026-08-28 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-31 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-31 2026-08-31 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-27 2026-08-27 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-26 2026-08-26 0002066836 us-gaap:ServiceAgreementsMember us-gaap:SubsequentEventMember 2026-08-26 0002066836 srt:DirectorMember us-gaap:SubsequentEventMember 2026-08-24 2026-08-24 0002066836 srt:DirectorMember us-gaap:SubsequentEventMember cnxu:PeriodFromMay212026Member 2026-08-24 0002066836 srt:DirectorMember us-gaap:SubsequentEventMember cnxu:PeriodFromMay212026Member 2026-08-24 2026-08-24 0002066836 srt:DirectorMember us-gaap:SubsequentEventMember cnxu:PeriodFromJune152026Member 2026-08-24 0002066836 srt:DirectorMember us-gaap:SubsequentEventMember cnxu:PeriodFromJune152026Member 2026-08-24 2026-08-24 0002066836 us-gaap:SubsequentEventMember 2026-09-04 2026-09-04 0002066836 cnxu:FounderAndFormerCeoMember 2026-07-31 0002066836 cnxu:FounderAndFormerCeoMember 2025-10-31 0002066836 srt:DirectorMember 2023-10-01 2023-10-31 0002066836 srt:DirectorMember 2025-04-01 2025-04-30 0002066836 srt:DirectorMember 2025-07-31 0002066836 srt:DirectorMember 2025-06-01 2025-06-05 0002066836 srt:DirectorMember cnxu:MilestoneTwoMember 2025-06-01 2025-06-05 0002066836 srt:DirectorMember cnxu:MilestoneThreeMember 2025-06-01 2025-06-05 0002066836 srt:DirectorMember 2025-11-03 2025-11-04 0002066836 cnxu:DirectorTwoMember 2023-10-01 2023-10-31 0002066836 cnxu:DirectorTwoMember 2025-03-01 2025-03-31 0002066836 cnxu:DirectorTwoMember 2025-10-30 2025-11-02 0002066836 cnxu:DirectorTwoMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorTwoMember 2025-05-01 2025-07-31 0002066836 cnxu:DirectorTwoMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorTwoMember 2024-11-01 2025-07-31 0002066836 cnxu:DirectorTwoMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneTwoMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneThreeMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2025-05-01 2025-05-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2025-05-01 2025-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2024-11-01 2025-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneTwoMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneThreeMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2025-10-30 2025-11-02 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2025-12-01 2025-12-31 0002066836 cnxu:CmoFormerDirectorFourAndFormerPresidentMember 2025-04-01 2025-04-30 0002066836 cnxu:CmoFormerDirectorFourAndFormerPresidentMember 2026-05-01 2026-07-31 0002066836 cnxu:CmoFormerDirectorFourAndFormerPresidentMember 2025-10-01 2025-10-15 0002066836 cnxu:CmoFormerDirectorFourAndFormerPresidentMember 2025-10-31 0002066836 cnxu:CeoPresidentAndDirectorSixMember 2025-10-01 2025-10-15 0002066836 cnxu:DirectorFiveMember 2025-10-01 2025-10-23 0002066836 cnxu:DirectorSevenMember 2025-10-01 2025-10-23 0002066836 cnxu:DirectorEightMember 2025-10-30 2025-11-02 0002066836 srt:ChiefFinancialOfficerMember 2026-05-01 2026-07-31 0002066836 srt:ChiefFinancialOfficerMember 2025-05-01 2025-07-31 0002066836 cnxu:DirectorSevenMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorSevenMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorEightMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorEightMember 2025-11-01 2026-07-31 0002066836 srt:ChiefFinancialOfficerMember 2026-07-31 0002066836 srt:ChiefFinancialOfficerMember 2025-10-31 0002066836 cnxu:DirectorFiveMember cnxu:MedicalAdvisoryAgreementMember 2025-10-30 2025-11-02 0002066836 cnxu:DirectorFiveMember 2026-07-31 0002066836 srt:ChiefFinancialOfficerMember 2025-10-01 2025-10-15 0002066836 srt:ChiefFinancialOfficerMember 2025-10-15 0002066836 cnxu:ChiefScienceOfficerMember 2025-10-01 2025-10-15 0002066836 cnxu:ChiefScienceOfficerMember 2025-10-15 0002066836 cnxu:CeoPresidentAndDirectorSixMember 2026-05-01 2026-07-31 0002066836 cnxu:CeoPresidentAndDirectorSixMember 2025-11-01 2026-07-31 0002066836 cnxu:CeoPresidentAndDirectorSixMember 2025-10-31 0002066836 cnxu:ChiefScienceOfficerMember 2025-10-31 0002066836 cnxu:DirectorFiveMember cnxu:MedicalAdvisoryAgreementMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorFiveMember cnxu:MedicalAdvisoryAgreementMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorFiveMember cnxu:MedicalAdvisoryAgreementMember 2026-07-31 0002066836 cnxu:DirectorFiveMember 2026-03-01 2026-03-17 0002066836 cnxu:DirectorFiveMember 2026-03-17 0002066836 cnxu:CeoPresidentAndDirectorSixMember 2026-07-31 0002066836 srt:ChiefFinancialOfficerMember 2023-11-01 2023-11-30 0002066836 srt:ChiefFinancialOfficerMember 2025-02-01 2025-02-28 0002066836 srt:ChiefFinancialOfficerMember 2025-11-01 2026-07-31 0002066836 srt:ChiefFinancialOfficerMember 2024-11-01 2025-07-31 0002066836 cnxu:DirectorEightMember 2025-11-30 0002066836 cnxu:DirectorSevenMember 2026-03-31 0002066836 cnxu:DirectorSevenMember 2026-04-30 0002066836 cnxu:DirectorSevenMember 2025-10-28 0002066836 cnxu:ChiefScienceOfficerMember 2026-05-01 2026-07-31 0002066836 cnxu:ChiefScienceOfficerMember 2025-11-01 2026-07-31 0002066836 cnxu:ChiefScienceOfficerMember 2025-06-01 2025-06-09 0002066836 cnxu:ChiefScienceOfficerMember 2025-05-01 2025-05-31 0002066836 cnxu:CeoPresidentAndDirectorSixMember cnxu:VestImmediatelyOnEffectiveDateMember 2025-10-01 2025-10-15 0002066836 cnxu:CeoPresidentAndDirectorSixMember cnxu:VestEachYearForFourYearsOnAnniversaryDateMember 2025-10-01 2025-10-15 0002066836 cnxu:DirectorSevenMember 2025-12-01 2025-12-31 0002066836 cnxu:DirectorSevenMember 2025-12-31 0002066836 cnxu:DirectorSevenMember 2026-07-31 0002066836 srt:DirectorMember cnxu:MilestoneTwoMember 2026-05-01 2026-07-31 0002066836 srt:DirectorMember cnxu:MilestoneTwoMember 2025-11-01 2026-07-31 0002066836 srt:DirectorMember cnxu:MilestoneThreeMember 2026-05-01 2026-07-31 0002066836 srt:DirectorMember cnxu:MilestoneThreeMember 2025-11-01 2026-07-31 0002066836 srt:DirectorMember 2026-05-01 2026-05-28 0002066836 srt:DirectorMember 2026-06-01 2026-06-18 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneTwoMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneTwoMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneThreeMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneThreeMember 2025-11-01 2026-07-31 0002066836 cnxu:ChiefCommercialOfficerMember 2026-06-10 2026-06-11 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2025-10-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneTwoMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneTwoMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneThreeMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneThreeMember 2025-11-01 2026-07-31 0002066836 cnxu:BoardMembersMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfBoardMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:NominatingAndGovernanceCommitteeMembersMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfNominatingAndGovernanceCommitteeMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:CompensationCommitteeMembersMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfCompensationCommitteeMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:AuditCommitteeMembersMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfAuditCommitteeMember cnxu:DirectorThreeAndFormerCeoMember 2026-06-02 2026-06-15 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2026-05-01 2026-05-22 0002066836 cnxu:DirectorThreeAndFormerCeoMember 2026-05-22 2026-05-22 0002066836 cnxu:CmoFormerDirectorFourAndFormerPresidentMember 2025-11-01 2026-07-31 0002066836 cnxu:BoardMembersMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfBoardMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:NominatingAndGovernanceCommitteeMembersMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfNominatingAndGovernanceCommitteeMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:CompensationCommitteeMembersMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfCompensationCommitteeMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:AuditCommitteeMembersMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfAuditCommitteeMember cnxu:DirectorFiveMember 2026-06-02 2026-06-15 0002066836 cnxu:DirectorFiveMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorFiveMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorFiveMember 2026-05-13 2026-05-14 0002066836 cnxu:DirectorFiveMember 2026-05-14 0002066836 cnxu:ChiefScienceOfficerMember 2024-11-01 2025-07-31 0002066836 cnxu:BoardMembersMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfBoardMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:NominatingAndGovernanceCommitteeMembersMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfNominatingAndGovernanceCommitteeMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:CompensationCommitteeMembersMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfCompensationCommitteeMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:AuditCommitteeMembersMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfAuditCommitteeMember cnxu:DirectorSevenMember 2026-06-02 2026-06-15 0002066836 cnxu:DirectorSevenMember 2026-05-11 2026-05-12 0002066836 cnxu:DirectorSevenMember 2026-05-12 0002066836 cnxu:DirectorSevenMember 2026-06-01 2026-06-18 0002066836 cnxu:DirectorSevenMember 2026-06-18 0002066836 cnxu:BoardMembersMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfBoardMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:NominatingAndGovernanceCommitteeMembersMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfNominatingAndGovernanceCommitteeMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:CompensationCommitteeMembersMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfCompensationCommitteeMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:AuditCommitteeMembersMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfAuditCommitteeMember cnxu:DirectorEightMember 2026-06-02 2026-06-15 0002066836 cnxu:BoardMembersMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfBoardMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:NominatingAndGovernanceCommitteeMembersMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfNominatingAndGovernanceCommitteeMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:CompensationCommitteeMembersMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfCompensationCommitteeMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:AuditCommitteeMembersMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfAuditCommitteeMember cnxu:DirectorNineMember 2026-06-02 2026-06-15 0002066836 cnxu:DirectorNineMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorNineMember 2025-11-01 2026-07-31 0002066836 cnxu:BoardMembersMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfBoardMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:NominatingAndGovernanceCommitteeMembersMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfNominatingAndGovernanceCommitteeMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:CompensationCommitteeMembersMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfCompensationCommitteeMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfAuditCommitteeMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:AuditCommitteeMembersMember cnxu:DirectorTenMember 2026-06-02 2026-06-15 0002066836 cnxu:DirectorTenMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorTenMember 2025-11-01 2026-07-31 0002066836 cnxu:BoardMembersMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfBoardMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 cnxu:NominatingAndGovernanceCommitteeMembersMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfNominatingAndGovernanceCommitteeMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 cnxu:CompensationCommitteeMembersMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfCompensationCommitteeMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 cnxu:AuditCommitteeMembersMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 cnxu:ChairmanOfAuditCommitteeMember cnxu:DirectorElevenMember 2026-06-02 2026-06-15 0002066836 srt:DirectorMember 2026-05-28 2026-05-28 0002066836 srt:DirectorMember cnxu:MilestoneOneMember 2025-06-01 2025-06-05 0002066836 srt:DirectorMember cnxu:MilestoneFourMember 2025-06-01 2025-06-05 0002066836 srt:DirectorMember cnxu:MilestoneFourMember 2026-05-01 2026-07-31 0002066836 srt:DirectorMember cnxu:MilestoneFourMember 2025-11-01 2026-07-31 0002066836 srt:DirectorMember cnxu:MilestoneOneMember 2026-05-01 2026-07-31 0002066836 srt:DirectorMember cnxu:MilestoneOneMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorElevenMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorElevenMember 2025-11-01 2026-07-31 0002066836 cnxu:HeadOfStrategyAndTransformationMember cnxu:ConsultingAgreementMember 2026-05-01 2026-07-31 0002066836 cnxu:HeadOfStrategyAndTransformationMember cnxu:ConsultingAgreementMember 2025-11-01 2026-07-31 0002066836 cnxu:HeadOfBusinessDevelopmentAndLicensingMember cnxu:ConsultingAgreementMember 2026-05-01 2026-07-31 0002066836 cnxu:HeadOfBusinessDevelopmentAndLicensingMember cnxu:ConsultingAgreementMember 2025-11-01 2026-07-31 0002066836 cnxu:HeadOfStrategyAndTransformationMember cnxu:ConsultingAgreementMember 2026-02-01 2026-02-09 0002066836 cnxu:HeadOfStrategyAndTransformationMember cnxu:ConsultingAgreementMember 2026-07-31 0002066836 cnxu:HeadOfBusinessDevelopmentAndLicensingMember cnxu:ConsultingAgreementMember 2026-07-31 0002066836 cnxu:CmoFormerDirectorFourAndFormerPresidentMember 2025-05-01 2025-07-31 0002066836 cnxu:CmoFormerDirectorFourAndFormerPresidentMember 2024-11-01 2025-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneFourMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneFourMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneFourMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneOneMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneOneMember 2024-11-01 2025-07-31 0002066836 cnxu:DirectorThreeAndFormerCeoMember cnxu:MilestoneOneMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneFourMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneFourMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneFourMember 2025-11-01 2026-07-31 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneOneMember 2025-06-01 2025-06-05 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneOneMember 2026-05-01 2026-07-31 0002066836 cnxu:DirectorTwoMember cnxu:MilestoneOneMember 2025-11-01 2026-07-31 0002066836 2025-04-10 0002066836 2025-04-10 2025-04-10 0002066836 2025-04-21 2025-04-21 0002066836 2026-05-01 0002066836 2026-09-10 0002066836 cnxu:LoanAgreementWithUniversityOfBritishColumbiaMember 2023-11-20 0002066836 cnxu:LoanAgreementWithUniversityOfBritishColumbiaMember 2024-10-31 0002066836 cnxu:LoanAgreementWithUniversityOfBritishColumbiaMember 2025-03-01 2025-03-04 0002066836 cnxu:LoanAgreementWithUniversityOfBritishColumbiaMember 2026-05-01 2026-07-31 0002066836 cnxu:LoanAgreementWithUniversityOfBritishColumbiaMember 2025-05-01 2025-07-31 0002066836 cnxu:LoanAgreementWithUniversityOfBritishColumbiaMember 2025-11-01 2026-07-31 0002066836 cnxu:LoanAgreementWithUniversityOfBritishColumbiaMember 2024-11-01 2025-07-31 0002066836 cnxu:InsuranceFundingAgreementMember 2026-05-12 0002066836 cnxu:InsuranceFundingAgreementMember 2026-05-12 2026-05-12 0002066836 cnxu:InsuranceFundingAgreementMember 2026-07-31 0002066836 cnxu:InsuranceFundingAgreementMember 2026-05-05 0002066836 cnxu:InsuranceFundingAgreementMember 2026-05-05 2026-05-05 iso4217:CAD pure shares iso4217:USD iso4217:USD shares P0Y P0Y 0002066836 false Q3 --10-31 10-Q true 2026-07-31 2026 false 001-43283 CONEXEU SCIENCES INC. NV 33-4814282 50 West Liberty Street Suite 880 Reno NV US 89501 424 333-5622 Common Stock CNXU NASDAQ Yes Yes Non-accelerated Filer true true false false 28206698 1971408 4808965 238208 25155 0 2000000 0 3037 2426 0 0 71326 4544274 549930 6756316 7458413 0 42177 71328 0 18475 0 9841 0 71641 0 16195 7431 74318 11237 22707 9819 163996 176884 7156074 7688711 784158 256296 45374 0 0 76000 39249 0 377598 0 22350 0 3722 3722 1272451 336018 33233 0 1305684 336018 0.001 0.001 50000000 50000000 0 0 0 0 0 0 0.001 0.001 250000000 250000000 27397164 27397164 18906066 18906066 27397 18906 22093270 11855307 -16270277 -4521520 5850390 7352693 7156074 7688711 105956 21288 126665 48503 5435 6640 23296 10604 3714 1474 9390 3132 1227253 52166 1410010 146386 3784642 465361 5446548 661957 100430 9363 125689 9513 164457 4148 172857 4148 26360 0 33042 0 1512974 457231 2848679 750033 34647 1282 58490 7632 216588 114872 809307 216219 235505 29134 328149 29134 270412 134662 399578 200795 7688373 1297621 11791700 2088056 -7688373 -1297621 -11791700 -2088056 0 0 0 43176 73169 0 73169 0 34214 386 129800 386 0 -43 0 4949 1677 -1378 -13688 2759 -37278 -949 42943 41372 -7725651 -1298570 -11748757 -2046684 0 0 0 0 -7725651 -1298570 -11748757 -2046684 -0.29 -0.29 -0.09 -0.09 -0.52 -0.52 -0.19 -0.19 26971608 26971608 14101995 14101995 22725622 22725622 10861432 10861432 0 0 18906066 18906 11855307 -4521520 7352693 927100 927 2942424 2943351 5525388 5525 2715036 2720561 288610 289 3081000 3081289 1750000 1750 1750 1493977 1493977 5526 5526 -11748757 -11748757 0 0 27397164 27397 22093270 -16270277 5850390 0 0 20916173 20916 15720093 -8544626 7196383 4961815 4962 2287672 2292634 269176 269 3036321 3036590 1250000 1250 1250 1044222 1044222 4962 4962 -7725651 -7725651 0 0 27397164 27397 22093270 -16270277 5850390 0 0 8528024 8528 684399 -597963 94964 4437500 4438 2013975 2018413 1849167 1849 831909 833758 482177 482177 149374 149374 207594 208 122690 122898 -2046684 -2046684 0 0 15022285 15023 4284524 -2644647 1654900 0 0 9505618 9506 1513316 -1346077 176745 3750000 3750 1464663 1468413 1766667 1767 765991 765991 455491 455491 85063 85063 -1298570 -1298570 0 0 15022285 15023 4284524 -2644647 1654900 -11748757 -2046684 12888 5477 10408 5127 -2740 0 0 43176 0 263453 0 149374 1493977 0 3081289 480496 73169 0 -9841 0 524865 1785 45374 0 2426 0 -3037 11962 -76000 0 3524559 42300 -18475 0 -9000 0 22350 0 -10099279 -1238410 76229 18668 2 0 0 40386 -76231 -59054 2000000 0 0 4189 2720561 0 5526 0 1750 0 2943351 2018413 92187 0 0 94206 30992 99627 7548009 1820391 2997 -4415 -2627501 522927 4834120 314616 2209616 833128 0 17547 0 0 0 353262 0 218724 71328 0 469785 0 81482 0 0 122897 <div> <div> <p style="margin-left:28pt;text-indent:-18.05pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1.<span style="display:inline-block;width:10pt"> </span></strong><strong>Nature of Operations</strong></span></span></p> <p style="text-align:justify;margin-left:28.1pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Conexeu Sciences Inc. ("CONEXEU" or the "Company") was incorporated on November 2, 2022, pursuant to the Business Corporations Act of British Columbia, Canada. CONEXEU is a regenerative medicine company committed to developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics with the use of patent protected advanced tissue engineering and biomaterial innovations.  The Company has a fiscal year-end of October 31.  On April 10, 2025, the Company was continued from the jurisdiction of British Columbia, Canada to a newly incorporated Nevada corporation. The registered offices of the Company, effective April 10, 2025, is located at 50 W Liberty St., Suite 880, Reno, Nevada, 89501.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 21, 2026, the Company began trading on the Nasdaq Trading Exchange ("Nasdaq") under symbol "CNXU".</span></span></p> <p style="text-align:justify;margin-left:28.1pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Risks and Uncertainties</i></span></span></p> <p style="text-align:justify;margin-left:28.1pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Disruption of global financial markets and a recession or market correction, including the ongoing military conflicts between Russia and Ukraine and the related sanctions imposed against Russia as well as the conflicts between Israel and Hamas, the significant tariffs imposed by the United States on imports from other countries, the military action taken against Iran and other global macroeconomic factors such as inflation and rising interest rates, could reduce the Company's ability to access capital, which could in the future negatively affect the Company's liquidity and could materially affect the Company's business and the value of its common stock.</span></span></p> <p style="text-align:justify;margin-left:28.1pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Segment Reporting</i></span></span></p> <p style="text-align:justify;margin-left:28pt;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ASC Topic No. 280, Segment Reporting ("ASC 280"), establishes standards for the way that public business enterprises report information about operating segments in their financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas, and major customers. The Company's business segments are based on the organization structure used by the chief operating decision maker for making operating and investment decisions and for assessing performance. Our chief executive officer, who is our chief operating decision maker, views the Company's operations and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics through use of patent protected advanced tissue engineering and biomaterial innovations.</span></span></p> </div> </div> <div> <div> <p style="margin-left:28pt;text-indent:-18pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>2.<span style="display:inline-block;width:10pt"> </span></strong><strong>Basis of Presentation</strong></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><i>Basis of Presentation</i></span></span></span></p> <p style="text-align:justify;margin-left:28pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These unaudited condensed interim financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements included in the Company's Annual Report for the fiscal year ended October 31, 2025. The accompanying unaudited condensed interim financial statements include all adjustments that are of a normal recurring nature and necessary for the fair presentation of the results for the interim periods presented. Results for interim periods are not necessarily indicative of results to be expected for the full year.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The functional and presentation currency of the Company is the United States Dollars.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Prior to its incorporation as a Nevada corporation, the Company's articles of incorporation had three classes of stock, Preferred Series A, Common Class A and Common Class B.  The articles of incorporation allowed for unlimited shares of each type to be issued, and the shares had no par value.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On April 10, 2025, the Company became incorporated in Nevada.  The Nevada articles of incorporation authorized two types of shares, preferred stock and common stock.  Each class of stock has a par value of $0.001 per share.  At the date of conversion, the Company only had Common Class A shares outstanding.</span></span></span></p> <div></div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These converted into common stock at a ratio of 1:1.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On April 21, 2025, the Board of Directors approved a 4:1 reverse stock split.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These unaudited condensed interim financial statements have been adjusted retrospectively for the change of incorporation and the reverse stock split.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><i>Use of Estimates</i></span></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The preparation of these unaudited condensed interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of these unaudited condensed interim financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><i>Going Concern</i></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These unaudited condensed interim financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. During the three months ending July 31, 2026, and 2025, the Company recorded a net loss of $7,725,651 and $1,298,570, respectively. During the nine months ending July 31, 2026, and 2025, the Company recorded a net loss of $11,748,757 and $2,046,684, respectively. As of July 31, 2026, and October 31, 2025, the Company had an accumulated deficit of $16,270,277 and $4,521,520, respectively.</span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of these unaudited condensed interim financial statements being issued. The ability of the Company to continue as a going concern is dependent upon the Company's ability to raise additional funds and implement its business plan. These unaudited condensed interim financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Such adjustments could be material.</span></span></span></p> <p style="margin-left:27pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>As of July 31, 2026, the Company had cash and cash equivalents in the amount of $1,971,408.  The continuation of the Company as a going concern is dependent upon its ability to obtain necessary debt or equity financing to continue operations until it begins generating positive cash flow. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory for the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.</span></span></span></p> </div> </div> 0.001 0.001 1:1 4:1 -7725651 -1298570 -11748757 -2046684 -16270277 -4521520 1971408 <div> <p style="margin-left:10pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3.<span style="display:inline-block;width:10pt"> </span></strong><strong>Summary of Significant Accounting Policies</strong></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The significant accounting policies applied in the preparation of these unaudited condensed interim financial statements are consistent with the accounting policies disclosed in the Company's audited financial statements for the year ended October 31, 2025.</span></span></p> <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Reclassifications</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain prior period amounts in the unaudited condensed consolidated financial statements have been reclassified to conform to the current period presentation. Specifically, regulatory expenses previously included in professional fees has been reclassified into Regulatory fees to better reflect the nature of the expenses. This reclassification had no effect on previously recorded operating expenses or net loss.</span></span></p> </div> <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Cash and Cash Equivalents</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents include cash on hand, deposits held with banks, funds in transit and when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of no more than three months. As of July 31, 2026, the Company had cash of $290,718 and cash equivalents of $1,680,690, for an aggregate amount of $1,971,408.  As of October 31, 2025, there was cash of $4,808,965 and $0 of cash equivalents. The total uninsured cash and cash equivalents balance as of July 31, 2026, and October 31, 2025, were $909,868 and $4,554,887, respectively.</span></span></p> </div> <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Investment</i></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has an investment of 19,327 shares of Series Seed Preferred Stock in a non-public company.  This investment is less than 20% ownership in the non-public company.  There is no observable market for the shares, and thus no readily determinable fair value.  Due to these circumstances, the Company accounts for the investment at cost less impairment.</span></span></p> </div> <p style="margin:0pt"> </p> <div></div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Restricted Cash</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted Cash equaling $238,208 represents the following: $75,905 held in a guaranteed investment certificate as collateral for the credit cards issued to the Company; $100 was received from the exercise of 100,000 milestone warrants and $162,203 of monies received relating to the warrant inducement program.. The monies received for the warrants are held in a trust account in the Company's name, that requires the Company's lawyers to approve transfers out of the account and are restricted until the warrants are issued and the funds are requested by the Company The shares for these warrants exercised were issued on June 8, 2026, and June 18, 2026, respectively. As of July 31, 2026, these monies remained in this account due to administrative reasons. On August 18, 2026, the Company received the $162,303 held in the trust account.</span></span></p> </div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Fair Value of Financial Instruments</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our financial assets and liabilities measured at fair value on a recurring basis consist primarily of prepaid expenses, accounts payable and accrued liabilities, due to shareholders, and loan payable. The carrying amount of prepaid expenses, accounts payable and accrued liabilities, due to shareholders approximate fair value because of the short-term maturity of such instruments.</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets and liabilities recorded in the unaudited condensed balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 - Quoted prices for similar assets or liabilities in active markets that are observable for the asset or liability either directly or indirectly through market corroboration, for substantially the full term of the financial instrument</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3 - Unobservable inputs for the asset or liability</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company had no assets or liabilities required to be accounted for under the fair value hierarchy.</span></span></p> </div> <div> <p style="text-indent:28.05pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Advertising Expenses</i></span></span></p> <p style="margin-left:28.05pt;text-indent:0.45pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Advertising expenses are expensed as incurred.  Advertising expenses for the three months ended July 31, 2026, and 2025 were $105,956 and $21,288, respectively. For the nine months ended July 31, 2026, and 2025, advertising expenses totaled $126,665 and $48,503, respectively</span></span></p> </div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Research and Development Expenses </i></span></span></p> <p style="margin-left:28.05pt;text-indent:0.45pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses are expensed as incurred and consist principally of internal and external costs, which include the cost of contract research services, laboratory supplies and development and manufacture of preclinical compounds and consumables for preclinical testing.  Research and development expenses for the three months ended July 31, 2026, and 2025 were $270,412 and $134,662, respectively. For the nine months ended July 31, 2026, and 2025, research and development expenses totaled $399,578 and $200,795, respectively</span></span></p> </div> <div> <div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Stock-Based Compensation</i></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies the provisions of ASC 718, Compensation-Stock Compensation ("ASC 718"), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options and warrants, in the unaudited condensed interim statements of operations.</span></span></p> </div> <div></div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For stock options and warrants issued to employees and members of the Company's Board of Directors (the "Board") for their services, the Company estimates each option's grant-date fair value using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option and warrant, the expected volatility of the Common Stock consistent with the expected life of the option and warrant, risk-free interest rates, and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options and warrants on a straight-line basis over the requisite service period, generally the vesting term. Forfeitures are recorded as incurred instead of estimated at the time of grant and revised.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-Employee Share-Based Payment Accounting, the Company accounts for stock options and warrants issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options and warrants that are in line with the process for valuing employee stock options and warrants noted above.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the Company's stock was determined by management and, in doing so, considered in part upon third-party 409A valuations through July 31, 2025.  A 409A valuation is an independent appraisal of a private company's common stock fair market value. The valuations were performed on the following dates: inception through December 30, 2024, December 31, 2024, June 5, 2025, and July 31, 2025.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company determined the fair value of the Company's stock from inception through December 30, 2024, by using the asset approach, as this was believed to be the most appropriate method due to very limited equity issuances, limited operations, and there being significant doubt about the Company's ability to continue as a going concern.  The fair value of the shares from this valuation was determined to be $0.05.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the Company's stock as of December 31, 2024, June 5, 2025, and July 31, 2025, was determined by using the market approach which was believed to be the most appropriate valuation methodology, whereby the fair value was equal to the price of the shares purchased in the most recent equity raises. The Company determined these dates for the valuations due to achievement of significant business milestones, including but not limited to, the continuation and restructuring of the Company from British Columbia, Canada to Nevada, USA, assignment of the IP patent, successes in the research and development programs and an increasing scope of potential markets for the Company's IP. The December 31, 2024, June 5, 2025, and July 31, 2025, valuations concluded that the fair value was equal to the most recent sale of equity securities, which was $0.80 (price post 4:1 reverse split), $0.40, and $2.00 respectively.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsequent to July 31, 2025, management determined the fair value of the shares was equal to the last raised price, as on July 31, 2025, the date the Company started its Regulation Crowdfunding offering at $2.00.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based on management's use of the market approach valuation, on October 28, 2025, the Company completed a private placement issuing 891,306 shares at a price of $2.30 per share.  Therefore, effective this date forward, until there is a raise supported at a different price, management determined that the fair market value of a Company's share was $2.30.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 23, 2026, the Company completed a private placement issuing 486,970 at a price of $4.00 per share.  Therefore, effective this date forward, until there is a raise supported at a different price, management determined that the fair market value of a Company's share was now $4.00.</span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 21, 2026, the Company's shares were listed on the Nasdaq and began trading publicly.  Therefore, any fair market valuation will now be determined by the closing price of the shares on any given date.</span></span></p> </div> <p style="margin:0pt"> </p> </div> <div></div> <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Net Loss Per Share</i></span></span></p> <p style="text-align:justify;margin-left:27.95pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company computes net loss per share in accordance with ASC 260, Earnings per Share ("EPS"). The Company computes basic loss per share by dividing the loss attributable to holders of Common Stock for the period by the weighted average number of shares of Common Stock outstanding during the period. The Company's warrants could potentially be exercised or converted into Common Stock and then share in the earnings of the Company. However, these convertible instruments were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the periods presented.</span></span></p> <p style="text-align:justify;margin-left:27.95pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the nine months ending July 31, 2026, and 2025, consist of the following (in common stock equivalents):</span></span></p> <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;border-color:#000000;font-size:10pt;margin-left:auto;margin-right:auto;width:90%;width:90%;width:90%"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;white-space:nowrap;width:60%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:1%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2026</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:2%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:1%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2025</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;background-color:rgb(230, 239, 255);width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>735,000</span></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>675,000</span></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:justify;background-color:rgb(230, 239, 255);width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted Share Units</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">150,000</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> </tr> </table> </div> <p style="text-align:justify;margin-left:28.05pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic EPS as calculated in these accompanying unaudited condensed interim financial statements have included the potential dilutive effect of the weighted average of vested penny warrants outstanding. Therefore, 1,250,000 penny warrants have been excluded in the total anti-dilutive warrants in the table above as of July 31, 2026. There were 1,000,000 penny warrants outstanding as of July 31, 2025.</span></span></p> </div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Fixed Assets </i></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fixed assets are stated at cost less accumulated depreciation.  Maintenance and repair charges are expensed as incurred.  Fixed assets are depreciated under the straight-line method using the following estimated useful lives:</span></span></p> <ul style="padding-left:0pt"> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equipment - 5 years</span></span></li> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lab Equipment - 5 years</span></span></li> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and fixtures - 5 years</span></span></li> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer equipment - 2 years.</span></span></li> </ul> </div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Leases</i></span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") Topic 842, Leases. The Company determines if an arrangement is a lease at inception. Right-of-use ("ROU") assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.</span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities are measured using the present value of future lease payments, discounted using the interest rate implicit in the lease, if readily determinable, or the Company's incremental borrowing rate. ROU assets are measured based on the corresponding lease liability, adjusted for lease incentives, initial direct costs, and prepaid lease payments.</span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that such options will be exercised. Lease expense for operating leases is recognized on a straight-line basis over the lease term.</span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company does not recognize ROU assets or lease liabilities for leases until the lease commencement date. Payments made prior to lease commencement are recorded as prepaid rent or other assets, depending on their nature.</span></span></p> </div> <p style="margin:0pt"> </p> <div></div> <div> <p style="text-align:justify;margin-left:28pt;text-indent:0pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Subsequent Events</i></span></span></p> <p style="text-align:justify;margin-left:28pt;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company evaluated subsequent events through September 14, 2026, the date in which these unaudited condensed interim financial statements were issued.</span></span></p> </div> </div> <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Reclassifications</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain prior period amounts in the unaudited condensed consolidated financial statements have been reclassified to conform to the current period presentation. Specifically, regulatory expenses previously included in professional fees has been reclassified into Regulatory fees to better reflect the nature of the expenses. This reclassification had no effect on previously recorded operating expenses or net loss.</span></span></p> </div> <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Cash and Cash Equivalents</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents include cash on hand, deposits held with banks, funds in transit and when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of no more than three months. As of July 31, 2026, the Company had cash of $290,718 and cash equivalents of $1,680,690, for an aggregate amount of $1,971,408.  As of October 31, 2025, there was cash of $4,808,965 and $0 of cash equivalents. The total uninsured cash and cash equivalents balance as of July 31, 2026, and October 31, 2025, were $909,868 and $4,554,887, respectively.</span></span></p> </div> 290718 1680690 1971408 4808965 0 909868 4554887 <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Investment</i></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has an investment of 19,327 shares of Series Seed Preferred Stock in a non-public company.  This investment is less than 20% ownership in the non-public company.  There is no observable market for the shares, and thus no readily determinable fair value.  Due to these circumstances, the Company accounts for the investment at cost less impairment.</span></span></p> </div> 19327 0.20 <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Restricted Cash</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted Cash equaling $238,208 represents the following: $75,905 held in a guaranteed investment certificate as collateral for the credit cards issued to the Company; $100 was received from the exercise of 100,000 milestone warrants and $162,203 of monies received relating to the warrant inducement program.. The monies received for the warrants are held in a trust account in the Company's name, that requires the Company's lawyers to approve transfers out of the account and are restricted until the warrants are issued and the funds are requested by the Company The shares for these warrants exercised were issued on June 8, 2026, and June 18, 2026, respectively. As of July 31, 2026, these monies remained in this account due to administrative reasons. On August 18, 2026, the Company received the $162,303 held in the trust account.</span></span></p> </div> 238208 75905 100 100000 162203 162303 <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Fair Value of Financial Instruments</i></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our financial assets and liabilities measured at fair value on a recurring basis consist primarily of prepaid expenses, accounts payable and accrued liabilities, due to shareholders, and loan payable. The carrying amount of prepaid expenses, accounts payable and accrued liabilities, due to shareholders approximate fair value because of the short-term maturity of such instruments.</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have categorized our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Assets and liabilities recorded in the unaudited condensed balance sheets at fair value are categorized based on a hierarchy of inputs, as follows:</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2 - Quoted prices for similar assets or liabilities in active markets that are observable for the asset or liability either directly or indirectly through market corroboration, for substantially the full term of the financial instrument</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3 - Unobservable inputs for the asset or liability</span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company had no assets or liabilities required to be accounted for under the fair value hierarchy.</span></span></p> </div> <div> <p style="text-indent:28.05pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Advertising Expenses</i></span></span></p> <p style="margin-left:28.05pt;text-indent:0.45pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Advertising expenses are expensed as incurred.  Advertising expenses for the three months ended July 31, 2026, and 2025 were $105,956 and $21,288, respectively. For the nine months ended July 31, 2026, and 2025, advertising expenses totaled $126,665 and $48,503, respectively</span></span></p> </div> 105956 21288 126665 48503 <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Research and Development Expenses </i></span></span></p> <p style="margin-left:28.05pt;text-indent:0.45pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses are expensed as incurred and consist principally of internal and external costs, which include the cost of contract research services, laboratory supplies and development and manufacture of preclinical compounds and consumables for preclinical testing.  Research and development expenses for the three months ended July 31, 2026, and 2025 were $270,412 and $134,662, respectively. For the nine months ended July 31, 2026, and 2025, research and development expenses totaled $399,578 and $200,795, respectively</span></span></p> </div> 270412 134662 399578 200795 <div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Stock-Based Compensation</i></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company applies the provisions of ASC 718, Compensation-Stock Compensation ("ASC 718"), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options and warrants, in the unaudited condensed interim statements of operations.</span></span></p> </div> <div></div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For stock options and warrants issued to employees and members of the Company's Board of Directors (the "Board") for their services, the Company estimates each option's grant-date fair value using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option and warrant, the expected volatility of the Common Stock consistent with the expected life of the option and warrant, risk-free interest rates, and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options and warrants on a straight-line basis over the requisite service period, generally the vesting term. Forfeitures are recorded as incurred instead of estimated at the time of grant and revised.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Non-Employee Share-Based Payment Accounting, the Company accounts for stock options and warrants issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options and warrants that are in line with the process for valuing employee stock options and warrants noted above.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the Company's stock was determined by management and, in doing so, considered in part upon third-party 409A valuations through July 31, 2025.  A 409A valuation is an independent appraisal of a private company's common stock fair market value. The valuations were performed on the following dates: inception through December 30, 2024, December 31, 2024, June 5, 2025, and July 31, 2025.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company determined the fair value of the Company's stock from inception through December 30, 2024, by using the asset approach, as this was believed to be the most appropriate method due to very limited equity issuances, limited operations, and there being significant doubt about the Company's ability to continue as a going concern.  The fair value of the shares from this valuation was determined to be $0.05.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of the Company's stock as of December 31, 2024, June 5, 2025, and July 31, 2025, was determined by using the market approach which was believed to be the most appropriate valuation methodology, whereby the fair value was equal to the price of the shares purchased in the most recent equity raises. The Company determined these dates for the valuations due to achievement of significant business milestones, including but not limited to, the continuation and restructuring of the Company from British Columbia, Canada to Nevada, USA, assignment of the IP patent, successes in the research and development programs and an increasing scope of potential markets for the Company's IP. The December 31, 2024, June 5, 2025, and July 31, 2025, valuations concluded that the fair value was equal to the most recent sale of equity securities, which was $0.80 (price post 4:1 reverse split), $0.40, and $2.00 respectively.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Subsequent to July 31, 2025, management determined the fair value of the shares was equal to the last raised price, as on July 31, 2025, the date the Company started its Regulation Crowdfunding offering at $2.00.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Based on management's use of the market approach valuation, on October 28, 2025, the Company completed a private placement issuing 891,306 shares at a price of $2.30 per share.  Therefore, effective this date forward, until there is a raise supported at a different price, management determined that the fair market value of a Company's share was $2.30.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 23, 2026, the Company completed a private placement issuing 486,970 at a price of $4.00 per share.  Therefore, effective this date forward, until there is a raise supported at a different price, management determined that the fair market value of a Company's share was now $4.00.</span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 21, 2026, the Company's shares were listed on the Nasdaq and began trading publicly.  Therefore, any fair market valuation will now be determined by the closing price of the shares on any given date.</span></span></p> </div> 0.05 0.8 4:1 0.4 2 2 891306 2.3 2.3 486970 4 4 <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Net Loss Per Share</i></span></span></p> <p style="text-align:justify;margin-left:27.95pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company computes net loss per share in accordance with ASC 260, Earnings per Share ("EPS"). The Company computes basic loss per share by dividing the loss attributable to holders of Common Stock for the period by the weighted average number of shares of Common Stock outstanding during the period. The Company's warrants could potentially be exercised or converted into Common Stock and then share in the earnings of the Company. However, these convertible instruments were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the periods presented.</span></span></p> <p style="text-align:justify;margin-left:27.95pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Potentially dilutive securities, which are not included in diluted weighted average shares outstanding for the nine months ending July 31, 2026, and 2025, consist of the following (in common stock equivalents):</span></span></p> <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;border-color:#000000;font-size:10pt;margin-left:auto;margin-right:auto;width:90%;width:90%;width:90%"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;white-space:nowrap;width:60%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:1%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2026</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:2%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:1%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2025</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;background-color:rgb(230, 239, 255);width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>735,000</span></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>675,000</span></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:justify;background-color:rgb(230, 239, 255);width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted Share Units</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">150,000</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> </tr> </table> </div> <p style="text-align:justify;margin-left:28.05pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic EPS as calculated in these accompanying unaudited condensed interim financial statements have included the potential dilutive effect of the weighted average of vested penny warrants outstanding. Therefore, 1,250,000 penny warrants have been excluded in the total anti-dilutive warrants in the table above as of July 31, 2026. There were 1,000,000 penny warrants outstanding as of July 31, 2025.</span></span></p> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;border-color:#000000;font-size:10pt;margin-left:auto;margin-right:auto;width:90%;width:90%;width:90%"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;white-space:nowrap;width:60%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:1%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2026</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:2%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:1%"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2025</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;white-space:nowrap;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;background-color:rgb(230, 239, 255);width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>735,000</span></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>675,000</span></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:justify;background-color:rgb(230, 239, 255);width:60%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted Share Units</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:right;background-color:rgb(230, 239, 255);width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">150,000</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid rgb(0, 0, 0);border-bottom:2.25pt double rgb(0, 0, 0);text-align:left;background-color:rgb(230, 239, 255);width:2%"> </td> </tr> </table> </div> 6733226 8733226 735000 675000 0 150000 1250000 1000000 <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Fixed Assets </i></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fixed assets are stated at cost less accumulated depreciation.  Maintenance and repair charges are expensed as incurred.  Fixed assets are depreciated under the straight-line method using the following estimated useful lives:</span></span></p> <ul style="padding-left:0pt"> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Equipment - 5 years</span></span></li> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lab Equipment - 5 years</span></span></li> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Furniture and fixtures - 5 years</span></span></li> <li style="margin-left:93.84pt;text-align:justify;padding-left:8.86pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Computer equipment - 2 years.</span></span></li> </ul> </div> P5Y P5Y P5Y P2Y <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Leases</i></span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") Topic 842, Leases. The Company determines if an arrangement is a lease at inception. Right-of-use ("ROU") assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.</span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities are measured using the present value of future lease payments, discounted using the interest rate implicit in the lease, if readily determinable, or the Company's incremental borrowing rate. ROU assets are measured based on the corresponding lease liability, adjusted for lease incentives, initial direct costs, and prepaid lease payments.</span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that such options will be exercised. Lease expense for operating leases is recognized on a straight-line basis over the lease term.</span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company does not recognize ROU assets or lease liabilities for leases until the lease commencement date. Payments made prior to lease commencement are recorded as prepaid rent or other assets, depending on their nature.</span></span></p> </div> <div> <p style="text-align:justify;margin-left:28pt;text-indent:0pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Subsequent Events</i></span></span></p> <p style="text-align:justify;margin-left:28pt;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company evaluated subsequent events through September 14, 2026, the date in which these unaudited condensed interim financial statements were issued.</span></span></p> </div> <div> <p style="margin-left:27pt;text-indent:-17.85pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4.<span style="display:inline-block;width:10pt"> </span></strong><strong>Fixed Assets</strong></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fixed Assets consist of the following:</span></span></p> <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:90%;border-color:#000000;margin-left:auto;margin-right:auto"> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong> </strong></span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2026</strong></span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>October 31, 2025</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Furniture and fixtures</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">661</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">400</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Lab equipment</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69,668</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:0.75pt solid #000000;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Computer equipment</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,184</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,268</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong> </strong></span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90,513</span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,668</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:0.75pt solid #000000;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Less: accumulated depreciation</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,195</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,431</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:2.25pt double #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fixed Assets, net</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>74,318</span></span></strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>11,237</span></span></strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> </table> </div> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation expense was $10,408 and $5,127 for the nine months ended July 31, 2026, and 2025, respectively.  For the three months ending July 31, 2026, and 2025, the depreciation expense was $5,483 and $2,296 respectively.</span></span></p> </div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:90%;border-color:#000000;margin-left:auto;margin-right:auto"> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong> </strong></span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>July 31, 2026</strong></span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>October 31, 2025</strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:right"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Furniture and fixtures</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">661</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">400</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Lab equipment</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">69,668</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:0.75pt solid #000000;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Computer equipment</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">20,184</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,268</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong> </strong></span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%"> </td> <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">90,513</span></span></td> <td colspan="1" style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">18,668</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:0.75pt solid #000000;vertical-align:bottom;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Less: accumulated depreciation</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">16,195</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:17%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,431</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:2.25pt double #000000;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fixed Assets, net</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>74,318</span></span></strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:17%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><span>11,237</span></span></strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> </table> </div> 661 400 69668 0 20184 18268 90513 18668 16195 7431 74318 11237 10408 5127 5483 2296 <p style="margin-left:28pt;text-indent:-18pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5.</strong><span style="text-indent:0pt;display:inline-block;width:10.49pt"> </span><strong>Taxes Receivable </strong></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has filed with the Canada Revenue Agency ("CRA") a Goods and Services Tax ("GST") return to claim the GST paid on Canadian expenses paid between September 21, 2024 (date of registration) and up to April 10, 2025, when the Company continued from the jurisdiction of British Columbia, Canada to a newly incorporated Nevada corporation and no longer qualified for claiming any GST paid.  The outstanding amount due July 31, 2026, and October 31, 2025, were $0 and $3,037, respectively.</span></span></p> 0 3037 <p style="margin-left:28pt;text-indent:-18pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6.</strong><span style="text-indent:0pt;display:inline-block;width:10.49pt"> </span><strong>Convertible Note Receivable </strong></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 14, 2025, the Company entered into a Memorandum of Understanding (the "MOU") with a private company (the "Target Company"), related to the potential acquisition of 100% of the assets of the Target Company. Although the general terms of the MOU were non-binding, the Company agreed to provide specific financing under terms that were binding for both parties. The Company entered into a convertible note receivable with the Target Company for an amount up to $87,500.  The convertible note accrues interest at 8% and has a maturity date of nine months from the earlier of when the Company agrees to terminate the MOU or August 22, 2025.  If the closing date of the acquisition occurs prior to the maturity date, all amounts owed will be forgiven and no amounts will remain due.  If the note matures prior to an acquisition occurring or due to the termination of the MOU, on the maturity date the outstanding amount must either be paid by the Target Company or the Company, at its discretion, can convert all of the outstanding principle and interest into Series Seed Preferred Stock of the Target Company at a price of $3.6905 per share.  On October 10, 2025, the Target Company and the Company mutually agreed to not extend and terminate an MOU and conclude any further acquisition negotiations, and the Company exercised its option to convert all principal and interest into shares under the terms of the Convertible Debenture.  As of October 31, 2025, $71,326 was outstanding under the note. On March 24, 2026, the Target Company converted the note along with interest for a total value of $71,328 and issued 19,327 shares of the Target company valued at $3.69 per share.  The Company is accounting for the investment at cost less impairment (See Note 2). As of July 31, 2026, the Company has not recorded any impairment.</span></span></p> 1 87500 0.08 3.6905 71326 71328 19327 3.69 <div> <p style="margin-left:10pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>7.<span style="display:inline-block;width:10pt"> </span>Patent</strong></span></span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><i>Patent Assignment Agreement with University of British Columbia ("UBC")</i></span></span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On November 20, 2023, the Company entered into a Patent Assignment Agreement ("PAA") with UBC.  Under the terms of the agreement, UBC agrees to transfer, sell and assign to the Company all of UBC's right, title and interest in and to the Patents.  However, the PAA will not be released to the Company until the Company has paid UBC $40,060 ($50,000 CAD) for expenses incurred and also fully pay the loan amount of $98,117 ($136,539 CAD) from the Loan Agreement entered into by both parties on November 20, 2023 (see Note 8).  Until that time, the PAA will be held in escrow until no later than November 20, 2027.  Should the Company fail to fully settle both payments on or before November 20, 2027, the PAA will not be released and will be destroyed.</span></span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company fully paid the loan and all interest due on March 4, 2025. The Patent Assignment was completed on April 7, 2025.</span></span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The total capitalized costs as of July 31, 2026, and October 31, 2025, were $186,703 and $186,703, respectively. </span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The patent has an expiration date of February 3, 2036.  Amortization expense for the nine months ended July 31, 2026, and 2025 was $12,888 and $5,477, respectively.  Amortization expense for the three months ending July 31, 2026, was $4,307. During the three months ending July 31, 2025, an amount of $4,344 was expensed.  Accumulated amortization as of July 31, 2026, and October 31, 2025, were $22,707 and $9,819, respectively.</span></span></span></p> </div> 40060 50000 98117 136539 186703 186703 12888 5477 4307 4344 22707 9819 <div> <p style="margin-left:10pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>8.<span style="display:inline-block;width:10pt"> </span></strong><strong>Debt</strong></span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Loan Agreement with University of British Columbia ("UBC")</i></span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the purchase of the patent, on November 20, 2023, the Company entered into a loan agreement with UBC.  The loan was for $136,539 CAD, bearing interest at 15%, and had a maturity date of November 20, 2026.  There are no required payments under the loan, as the full amount was due upon maturity.</span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of October 31, 2024, the outstanding principal was $98,117 ($136,539 CAD).</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 4, 2025, the Company paid UBC a total of $148,037 ($213,795 CAD) in settlement of the PAA.  The settlement included interest of $27,256 CAD and an accounts payable of $50,000 CAD.</span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense was $0 and $43 during the three months ended July 31, 2026, and 2025, respectively. For the nine months ended July 31, 2026, and 2025, interest expense totaled $0 and $4,949, respectively.</span></span></p> <p style="text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Insurance Funding Agreement</i></span></span></p> <p style="text-align:justify;margin-left:27pt;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On May 5, 2026, the Company obtained an insurance policy with total premiums equaling $625,535 on which a cash down payment of $155,750 was paid. On May 12, 2026, the Company entered into an agreement with a third party to finance the remaining premiums of $469,785.  The financing agreement had nine equal monthly payments of $53,943 each month, accrued interest at a rate of 7.95% and a maturity date of February 5, 2027.  Total financing charges equal $15,699. As of July 31, 2026, the outstanding balance, including principal and interest, was $377,598 and was reported on the unaudited condensed interim balance sheet as insurance funding agreement.</span></span></p> </div> 136539 0.15 98117 136539 148037 213795 27256 50000 0 43 0 4949 625535 155750 469785 53943 0.0795 15699 377598 <div> <div> <p style="margin-left:10pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>9.</strong></span></span><span style="padding-left:8pt"> </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Right of Use Asset</strong></span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On March 23, 2026, the Company entered into a 24-month licence agreement commencing May 1, 2026, with monthly base lease fees of approximately $5,016 (comprised of $769 for office space and $4,246 for lab space), plus applicable operating costs and taxes, payable monthly in advance, with a one-month rent-free early access period prior to commencement and two additional base rent "holiday" months (one in each lease year) during which no base rent is payable.</span></span></p> <div></div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective May 1, 2026, the Company began to recognize the lease in accordance with ASC 842.  As of May 1, 2026, the Company recognized an Operating Lease - Right of Use non-current asset of $81,482 and a lease liability of $81,482. As of July 31, 2026, there was accumulated amortization of $9,841.  A corresponding current lease liability of $39,249 and a long-term lease liability of $33,233.</span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When measuring lease liabilities for leases that classified as operating leases, the Company discounted lease payments using the estimated incremental borrowing rate at the later of the lease inception or May 1, 2026, the date of adoption of the ASC 842.  The weighted average incremental borrowing rate applied was 3.75%.</span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table presents the net lease cost and other supplemental lease information:</span></span></p> <div style="margin-left:28.8pt"> <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Nine months ending July 31,</strong></span></span></td> <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease cost:</span></span></td> <td style="vertical-align:bottom;text-align:justify;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:justify;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:justify;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease cost</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,378</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term lease cost</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net lease cost</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,378</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for operating lease liabilities</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,478</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> </table> </div> </div> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of July 31, 2026, the estimated future minimum lease payments, excluding non-lease components, are as follows:</span></span></p> <div style="margin-left:28.8pt"> <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fiscal Year</strong></span></span></td> <td style="vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026 (remaining)</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,217</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41,127</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22,433</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum annual lease payments</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">74,777</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: Imputed interest</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,295</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liability</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">72,482</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> </table> </div> </div> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the execution of the lease agreement, the Company paid a security deposit of $18,475. A portion of the deposit will be applied toward rental payments of $6,158 within the first twelve months following lease commencement, with the remaining balance of $12,317, which includes the last month lease payment and a refundable security deposit upon expiration of the lease term, subject to the terms of the agreement.</span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of July 31, 2026, the Company has recognized the security deposit of $18,475 as a non-current asset in the accompanying unaudited condensed balance sheet.</span></span></p> </div> </div> 5016 769 4246 81482 81482 9841 39249 33233 0.0375 <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td colspan="4" style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Nine months ending July 31,</strong></span></span></td> <td colspan="1" style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2026</strong></span></span></td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2025</strong></span></span></td> <td style="vertical-align:bottom;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease cost:</span></span></td> <td style="vertical-align:bottom;text-align:justify;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:justify;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:justify;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:right;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease cost</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,378</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Short-term lease cost</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net lease cost</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,378</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for operating lease liabilities</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,478</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> </table> </div> 10378 0 0 0 10378 0 7478 0 <div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-size:10pt;width:100%;border-color:#000000"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Fiscal Year</strong></span></span></td> <td style="vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> <td style="vertical-align:bottom;text-align:justify;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026 (remaining)</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11,217</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2027</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">41,127</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2028</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">22,433</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total future minimum annual lease payments</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">74,777</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:rgb(230, 239, 255)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: Imputed interest</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:12%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,295</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liability</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:12%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">72,482</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> </table> </div> 11217 41127 22433 74777 2295 72482 18475 6158 12317 18475 <div> <div> <p style="font-family:Times New Roman;margin-left:10pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>10.</strong>   <strong>Related Party Transactions</strong></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Founder and Former CEO</i></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Founder and then Chief Executive Officer ("CEO") made non-interest-bearing advances to the Company with no specific terms of repayment that are due on demand. The outstanding amounts as of July 31, 2026, and October 31, 2025, were $3,722 and $3,722, respectively. These are disclosed as due to shareholders on the unaudited condensed balance sheets.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Director 1 (Former)</i></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company entered into a consulting agreement with a company of which Director 1 controls in October 2023. In accordance with the agreement, it was agreed to provide consulting services, including but not limited to, provide the Company with corporate management services, (ii) provide the Company with introductions to certain entities which could form strategic alliances or partnerships with the Company, including assisting with negotiations with respect to any such alliance or partnership, and (iii) assist the Company with strategic planning and, Director 1 received a monthly fee of $7,500 and could earn discretionary performance-based bonuses. This agreement was in effect through March 2025. Effective April 2025, the Company entered into a new consulting agreement with Director 1, which had an indefinite term, and increased the monthly fee of $10,000.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Director 1 earned certain discretionary bonuses in the form of shares and warrants during the nine months ended July 31, 2025.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 15, 2025,<span><span><span><span> Director 1 was granted 82,500 shares and 82,500 warrants. The shares vested immediately and had a fair value of $66,000. The warrants vested immediately, had an exercise price of $0.80 and a life of two years. The fair value of the warrants was $26,686. The share-based compensation expense for the nine months ended July 31, 2025, was $92,686.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The total expense, exclusive of the share-based compensation, was $25,000 and $113,500 during the three and nine months ended July 31, 2025. These expenses are included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.  As of July 31, 2025, $10,000 was reported as unpaid.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 5, 2025, the Company and Director 1 entered into a consulting service agreement for 1,000,000 Performance Warrants. The warrants have an exercise price of $0.001 and a term of 5 years. The milestones are as follows:</span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="text-align:justify;margin-left:45pt;margin-bottom:0pt;margin-top:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>Milestone 1</strong> - </span></span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">250,000 Warrants shall vest upon the Company completing and receiving the results of the three-month Collagen Study in Boston, MA. The grant date fair value of these warrants was $99,778. This milestone was successfully achieved on July 8, 2025.  The fair value of these warrants is expensed over the expected vesting term. During the three and nine months ended July 31, 2025, an expense of $99,778 was recognized.</span></span></p> <p style="font-family:Times New Roman;margin-top:0pt;margin-left:45.8pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>Milestone 2</strong> - 250,000 Warrants shall vest upon the Company listing its shares of common stock on The Nasdaq Stock Market, LLC, or any such other recognized stock exchange in North America. The grant date fair value of these warrants was $99,782. The fair value of these warrants will be expensed in its entirety upon achievement of this milestone. This milestone was successfully achieved on May 21, 2026. During the three and nine months ended July 31, 2026, an expense of $99,782 was fully recognized and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-top:0pt;margin-left:45.8pt;text-align:justify;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>Milestone 3</strong> - 250,000 Warrants shall vest upon the Company's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed. The grant date fair value of these warrants was $99,783. The fair value of these warrants will be expensed in its entirety upon achievement of this milestone. This milestone was successfully achieved on June 17, 2026. During the three and nine months ended July 31, 2026, an expense of $99,783 was fully recognized and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-top:0pt;margin-left:45.8pt;text-align:justify;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>Milestone 4</strong> - </span></span></span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">250,000 Warrants shall vest upon the Company submitting a 510(k) application to the FDA. The grant date fair value of these warrants was $99,782. The Company assessed a greater than 70% probability that this would occur. As of October 31, 2025, the Company anticipated that this would occur on June 30, 2026. As of July 31, 2026, the Company anticipates that this will now occur on March 31, 2027. The expense for the three and nine months ended July 31, 2026, was $11,745 and $34,852, respectively, and are included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 23, 2025, Director 1 resigned from the board and the consulting agreement with the company of which Director 1 is a director was mutually terminated.</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On November 4, 2025, the Company and former Director 1 reached a separation agreement wherein a one-time lump sum payment of $50,000 was paid to the company in which the former director is a director.  It was also agreed that the options previously granted to the former director on June 9, 2025, would continue to maintain the original expiry date of June 8, 2030, rather than expiring 90 days following termination or resignation or January 31, 2026. The full $50,000 of this expense was incurred during the nine months ending July 31, 2026, and is included within management and director's salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 28, 2026, this former director exercised 400,000 milestone warrants for total gross proceeds of $400.  The Company issued 400,000 common shares in connection with the warrant exercise.</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 18, 2026, this former director exercised 250,000 milestone warrants for total gross proceeds of $250.  The Company issued 250,000 common shares in connection with the warrant exercise.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Director 2 &amp; CCO</i></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company entered into a consulting agreement with Director 2 in October 2023. In accordance with the agreement, it was agreed to provide consulting services, including but not limited to, provide the Company with corporate management services, provide the Company with introductions to certain entities which could form strategic alliances or partnerships with the Company, including assisting with negotiations with respect to any such alliance or partnership, and assist the Company with strategic planning and, Director 2 received a monthly fee of $7,500 and could earn discretionary performance-based bonuses. The agreement was in effect through February 2025.</span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Effective March 2025, the Company entered into a new consulting agreement with Director 2, which had an indefinite term, and increased the monthly fee of $10,000.  On November 1, 2025, this amount was revised to $9,900 per month. On December 14, 2025, Director 2 and the Company agreed to mutually terminate the consulting agreement.</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The total expense incurred in connection with these agreements was $0 and $30,000 during the three months ended July 31, 2026, and 2025, respectively.  For the nine months ended July 31, 2026, and 2025 the total expense incurred equalled $19,800 and $80,000, respectively.  These expenses are included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On December 15, 2025, the board agreement between Director 2 and the Company was revised.  Effective January 1, 2026, the Director was entitled to quarterly compensation of $45,000 to be paid in monthly instalments of $15,000.  For the three and nine months ended July 31, 2026, a total of $30,000 and $90,000, respectively, is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of July 31, 2026, and 2025, there were no outstanding payables.</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 5, 2025, the Company and Director 2 entered into a consulting service agreement for 1,000,000 Performance Warrants. The warrants have an exercise price of $0.001 and a term of 5 years. The milestones are as follows:</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:45.8pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Milestone 1</strong> - </span></span></span></span>250,000 Warrants shall vest upon the Company completing and receiving the results of the three-month Collagen Study in Boston, MA. The grant date fair value of these warrants was $99,778. This milestone was successfully achieved on July 8, 2025.  The fair value of these warrants is expensed over the expected vesting term. During the three and nine months ended July 31, 2025, an expense of $99,778 was recognized.</span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:45.8pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Milestone 2</strong> - 250,000 Warrants shall vest upon the Company listing its shares of common stock on The Nasdaq Stock Market, LLC, or any such other recognized stock exchange in North America. The grant date fair value of these warrants was $99,782. The fair value of these warrants will be expensed in its entirety upon achievement of this milestone. This milestone was successfully achieved on May 21, 2026. During the three and nine months ended July 31, 2026, an expense of $99,782 was fully recognized and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:45.8pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Milestone 3</strong> - 250,000 Warrants shall vest upon the Company's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed. The grant date fair value of these warrants was $99,783. The fair value of these warrants will be expensed in its entirety upon achievement of this milestone. This milestone was successfully achieved on June 17, 2026. During the three and nine months ended July 31, 2026, an expense of $99,783 was fully recognized and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:45.8pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Milestone 4</strong> - </span></span></span></span>250,000 Warrants shall vest upon the Company submitting a 510(k) application to the FDA. The grant date fair value of these warrants was $99,782. The Company assessed a greater than 70% probability that this would occur. As of October 31, 2025, the Company anticipated that this would occur on June 30, 2026. As of July 31, 2026, the Company anticipates that this will now occur on March 31, 2027. The expense for the three and nine months ended July 31, 2026, was $11,745 and $34,852, respectively, and are included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 11, 2026, the board of directors, upon the recommendation of both the nominating and governance and compensation committees, approved the appointment of Director 2 as the Chief Commercial Officer ("CCO") effective June 15, 2026, along with their associated compensation package. Director 2 will continue to serve on the board as a non-independent executive board member.  As part of their role as CCO, they will become a full-time employee, their annual salary is $270,000, additional incentives include, an annual discretionary bonus, a milestone equity award up to a maximum of 0.75% of the Company's common shares on an issued and outstanding basis at the time of the equity grant, plus $37,500 upon the date of the completion of a financing of $20 million at a minimum of $150 million pre-money market capitalization. If the financing completed is a minimum of $15 million at a minimum of $150 million pre-money market capitalization, then then two-thirds of the $37,500 or $24,750 will be earned and paid out.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Director 3 and former CEO (May to October 2025)</i></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company entered into a consulting agreement with Director 3 in May 2025 to serve as the CEO. In accordance with the agreement, through a company that Director 3 controls, he would provide services related to his role as CEO, including but not limited to, the overall business strategy, identify and develop relationships with strategic business partners and provide oversight of the overall day-to-day business activities and received a monthly fee of $12,500. The agreement had an indefinite term.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>For the three months ended July 31, 2026, and 2025, the Company incurred, $37,500 and $0, respectively.  For the nine months ended July 31, 2026, and 2025, the total expense was $212,500 and $0, respectively.  The expense is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>During the nine months ended July 31, 2026, Director 3 earned a one-time incentive payment of $100,000 in recognition of their efforts to date in helping the Company achieve its short-term goals and building to achieve its longer-term goals.</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of July 31, 2026, and 2025, $20,000 and $0, respectively, was reported under accounts payable and accrued liabilities - related parties on the unaudited condensed balance sheet of the same date.</span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 5, 2025, the Company and Director 3 entered into a consulting service agreement for 2,000,000 Performance Warrants. The warrants have an exercise price of $0.001 and a term of 5 years. The milestones are as follows:</span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:45.8pt;margin-bottom:0pt;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Milestone 1</strong> - </span></span></span></span>500,000 Warrants shall vest upon the Company completing and receiving the results of the three-month Collagen Study in Boston, MA. The grant date fair value of these warrants was $199,555. This milestone was successfully achieved on July 8, 2025. The fair value of these warrants is expensed over the expected vesting term. During the three and nine months ended July 31, 2025, an expense of $199,555 was recognized.</span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:45.8pt;margin-bottom:0pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Milestone 2</strong> - 500,000 Warrants shall vest upon the Company listing its shares of common stock on The Nasdaq Stock Market, LLC, or any such other recognized stock exchange in North America. The grant date fair value of these warrants was $199,563. The fair value of these warrants will be expensed in its entirety upon achievement of this milestone. This milestone was successfully achieved on May 21, 2026. During the three and nine months ended July 31, 2026, an expense of $199,563 was fully recognized and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:45.8pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Milestone 3</strong> - 500,000 Warrants shall vest upon the Company's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed. The grant date fair value of these warrants was $199,566. The fair value of these warrants will be expensed in its entirety upon achievement of this milestone. This milestone was successfully achieved on June 17, 2026. During the three and nine months ended July 31, 2026, an expense of $199,566 was fully recognized and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="text-align:justify;margin-left:45pt;margin-bottom:10pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong style="font-family:Times New Roman, Times, serif">Milestone 4</strong><span> - </span></span></span></span></span>500,000 Warrants shall vest upon the Company submitting a 510(k) application to the FDA. The grant date fair value of these warrants was $199,563. The Company assessed a greater than 70% probability that this would occur. As of October 31, 2025, the Company anticipated that this would occur on June 30, 2026. As of July 31, 2026, the Company anticipates that this will now occur on March 31, 2027. The expense for the three and nine months ended July 31, 2026, was $23,490 and $69,703, respectively, and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:10pt;font-size:10pt;margin-left:28pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The CEO resigned October 22, 2025, and continued as a non-executive Director.</span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Effective November 1, 2025, Director 3 entered into a board agreement to serve on the Company's board of directors for an indefinite term. In connection with this agreement, Director 3 is entitled to a $15,000 quarterly directors' fee. On June 15, 2026, board members were issued a compensation notice, advising them of adjustments to their board compensation. All board members will be eligible for an annual cash compensation of $50,000; the chair of the board will receive an annual compensation of $100,000.  Additionally, on an annual basis, each board member will be granted the equivalent of $100,000 worth of Restricted Share Units, the number of shares will be determined based on the closing price on the grant date.  Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months.  The chairman of the board will receive the equivalent of $150,000 under the same terms as the other board members.  Eligibility will be determined on the "continuous service" conditions as defined in the board member's agreement.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Furthermore, all board members serving on any of the committees will receive the following; Nominating and Governance committee members will receive $5,000 per year, with the chair of the committee receiving $7,500; Compensation committee members will receive $6,000 per year, with the chair of the committee receiving $12,000 and, Audit committee members will receive $7,500 per year, with the chair of the committee receiving $15,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the three-and nine-months ending July 31, 2026, the total expense incurred in connection with the original agreement and the new compensation notice was $20,000 and $50,000, respectively and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations</span></span></p> <p style="font-family:Times New Roman;margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In December 2025, Director 3 exercised 500,000 of their vested milestone warrants for gross proceeds of $500. The Company issued 500,000 common shares in connection with the warrant exercise.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On May 22, 2026, Director 3 exercised 500,000 of their vested milestone warrants for gross proceeds of $500.  The Company issued 500,000 common shares in connection with the warrant exercise.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>CMO, former Director 4 and former President</i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company entered into a consulting agreement with a company that Director 4 controls in April 2025 to serve as the Chief Medical Officer ("CMO"). In accordance with the agreement, Director 4 would provide services, including but not limited to, strategic direction, scientific support, business development support, research programs, budgeting, and medical affairs and received a monthly fee of $10,000. The agreement was in effect through October 2025.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the three and nine months ended July 31, 2025, an expense of $30,000 and $40,000, respectively, was incurred and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.  As of July 31, 2025, there was no accounts payable outstanding.</span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;text-align:justify;margin-left:27pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On April 1, 2025, the Company granted the CMO 100,000 stock options with an exercise price of $0.40, that vest 6 months from the effective date of their service agreement or from April 1, 2025, and have a 24-month expiry date from the grant date or April 1, 2027.  The fair value of the stock options granted was determined to be $57,527.  In connection with these options, $28,936 and $38,052 in stock compensation was recognized during the three and nine months ended July 31, 2025, respectively, and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 15, 2025, the CMO became a full-time employee and agreed to a remuneration package of an annual salary of $240,000 or $20,000 per month, along with an inducement signing bonus of $35,000 and, when available, access to a Company benefits plan.  Since February 1, 2026, the CMO is now enrolled in a Company benefit plan for Canadian employees.  Until that plan is in place it was agreed to pay the CMO an additional monthly stipend of $3,000 for medical coverage.  Additionally, the CMO was granted shares of the Company equaling 0.5% of the common shares of the Company on an issued and outstanding basis at the time of the effective date of the employment agreement, to be immediately vested.  On October 15, 2025, this represented a total of 87,861 common shares with a fair value of $2.00 per share or a total of $175,723.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 22, 2025, he resigned from his role as President and Director, while maintaining his position as CMO.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>As at October 31, 2025, the Company recognized wages payable of $45,000 on the condensed balance sheets.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Director 5 </i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On May 14, 2025, a new Director 5 was appointed to the Company's board of directors.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 23, 2025, Director 5 entered into a new board agreement with the Company. The agreement has an effective date of October 23, 2025, an indefinite term, and beginning November 2025, entitles the Director to quarterly compensation of $15,000 to be paid in common shares, based on the price of the Company's most recent financing at the time. On June 15, 2026, board members were issued a compensation notice, advising them of adjustments to their board compensation. All board members will be eligible for an annual cash compensation of $50,000; the chair of the board will receive an annual compensation of $100,000.  Additionally, on an annual basis, each board member will be granted the equivalent of $100,000 worth of Restricted Share Units, the number of shares will be determined based on the closing price on the grant date.  Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months.  The chairman of the board will receive the equivalent of $150,000 under the same terms as the other board members.  Eligibility will be determined on the "continuous service" conditions as defined in the board member's agreement. </span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Furthermore, all board members serving on any of the committees will receive the following; Nominating and Governance committee members will receive $5,000 per year, with the chair of the committee receiving $7,500; Compensation committee members will receive $6,000 per year, with the chair of the committee receiving $12,000 and, Audit committee members will receive $7,500 per year, with the chair of the committee receiving $15,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>For the three and nine months ended July 31, 2026, a total expense of $15,125 and $45,125, respectively, had been incurred and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.  As of July 31, 2026, $7,500 due for the quarter was reported under liabilities to be settled with shares on the unaudited condensed balance sheet. Effective June 15, 2026, Director 5 has agreed to accept cash payment for his director's fees rather than receive shares and he has directed that those cash payments be made to a company of which is has controlling interests.</span></span></span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;text-align:justify;margin-left:27pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On November 1, 2025, Director 5 entered into a new medical advisory agreement. In accordance with the agreement, the director will be compensated monthly $9,900 which will be paid through issuance of common shares based on the most recent financing at the time of issuance, and or if the Company is publicly traded the 20-day volume weighted average pricing of common shares immediately prior to the payment date.  Additionally, should the medical advisor be directly responsible for a referral or introduction to a third party that makes an investment in the Company, or its assets, or acquires all or portion of the Company's assets the Director will be entitled to a fee equal to 2.5% of the value of the transaction, to a maximum of $5,000,000. This fee can be paid either in shares or cash, at the discretion of the director.  The agreement had an indefinite term. For the three and nine months ended July 31, 2026, a total expense of $29,700 and $89,100, respectively, had been incurred and is included in consulting on the unaudited condensed interim statements of operations.  As of July 31, 2026, $14,850 was reported under liabilities to be settled with shares on the unaudited condensed balance sheet.  Effective June 15, 2026, Director 5 has agreed to accept cash payment for his medical advisory agreement rather than receive shares and he has directed that those cash payments be made to a company of which he has controlling interests.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On March 17, 2026, the Company issued 19,434 shares at a price of $2.30 per share to Director 5 in settlement of fees owed related to their advisory and director's agreements.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On May 14, 2026, the Company issued 11,175 shares at a fair value of $4.00 per share to settle liabilities with Director 5.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>As of July 31, 2026, a total of $22,350 was included in liabilities to be settled in shares on the unaudited condensed balance sheet of the same date.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:13.4pt;text-indent:14.4pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>CEO, President and Director 6 </i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 15, 2025, the new CEO became a full-time employee and agreed to a remuneration package of an annual salary of $300,000 or $25,000 per month and, when available, access to a Company benefits plan.  Until that plan is in place it was agreed to pay the CEO an additional monthly stipend of $2,000 for medical coverage.  Since January 1, 2026, the CEO is now enrolled in a Company benefit plan. Additionally, the CEO was granted shares of the Company up to 2.5% of the common shares of the Company on an issued and outstanding basis at the time of the effective date of the employment agreement. This amounted to a total of 439,306 shares granted with a fair value of $878,612. Of these shares, 0.5% (87,861) will vest immediately on the effective date of this agreement and then 0.5% (87,861) will vest each year for four (4) years on the anniversary date of this agreement. </span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>For the three and nine months ended July 31, 2026, the Company expensed $92,253 and $289,796, respectively, as part of the management and directors' salaries and fees on the unaudited condensed interim statements of operations relating to these shares. As of July 31, 2026, there is potential future unrecognized expense of $413,094.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>As of October 31, 2025, the Company recognized wages payable of $15,000 on the condensed balance sheets.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>CFO</i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company entered into a consulting agreement with a company that is controlled by the Chief Financial Officer ("CFO") in November 2023. In accordance with the agreement, it was agreed that in addition to fulfilling the responsibilities of the Company's CFO, additional services would include, but are not limited to, oversight of all accounting matters, bookkeeping services and general day-to-day operations and the CFO received minimum monthly compensation of $1,500. This agreement was in effect through January 2025. Effective February 2025, the Company entered into a new consulting agreement with the CFO, which had an indefinite term, and increased the minimum monthly compensation to $4,000.</span></span></span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;text-align:justify;margin-left:27pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The total expense incurred in connection with these agreements was $0 and $12,500 during the three months ended July 31, 2026, and 2025, respectively. For the nine months ended July 31, 2026, and 2025, a total expense of $0 and $28,500, respectively were incurred. These expenses are included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>As of July 31, 2026, and October 31, 2025, $2,280 and $0, respectively, were unpaid to a company that is controlled by the CFO and that provides bookkeeping services to the Company and are included in accounts payable and accrued liabilities - related party in the unaudited condensed balance sheets of the same date.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>During the nine months ended July 31, 2025, the Company converted outstanding payables of $10,875 owed to the CFO into 13,594 shares with a fair value of $640. This resulted in a gain on conversion of $10,235. This is included within gain on conversion of payables on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 15, 2025, the CFO became a part-time employee and agreed to a remuneration of a maximum annual salary of $216,000 or $18,000 per month.  At the time of agreeing to this employment agreement, the CFO was committing an estimate one-third of his time.  Additionally, the CFO was granted shares of the Company equaling 0.25% of the common shares of the Company on an issued and outstanding basis at the time of the effective date of the employment agreement, to be immediately vested.  On October 15, 2025, this represented a total of 43,931 common shares with a fair value of $2.00 per share or a total of $87,861.  Since January 1, 2026, the CFO has been committed to a full-time schedule. Since February 1, 2026, the CFO is now enrolled in a Company benefit plan for Canadian employees.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>As of October 31, 2025, the Company recognized wages payable of $6,000 on the condensed balance sheets.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>CSO</i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The Company entered into a consulting agreement with this consultant in May 2025 to serve as the Chief Science Officer ("CSO"). In accordance with the agreement, the CSO agreed to provide services, including but not limited to, advancing the Company's core biomaterial technology, building the Company's future product pipeline, develop, test, and expand the applications of the Company's proprietary collagen-based platform across multiple medical and surgical markets.  The CSO received a monthly fee of $10,000. The agreement had an indefinite term.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;margin-bottom:0pt;text-align:justify;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On June 9, 2025, the Company granted to the CSO, 50,000 stock options with an exercise price of $0.40 and that vest 12 months from the grant date. The fair value of the stock options granted was determined to be $18,553. During the three and nine months ended July 31, 2026, the Company expensed $2,033 and $11,233 (nine months ending July 31, 2025 - $2,643), respectively, as part of the management and directors' salaries and fees on the unaudited condensed statements of operations related to the value of the options granted and now vested. On June 9, 2026, the stock options fully vested and had been fully expensed.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 15, 2025, the CSO became a full-time employee and agreed to a remuneration package of an annual salary of $240,000 or $20,000 per month and, when available, access to a Company benefits plan. Since January 1, 2026, the CSO is now enrolled in a Company benefit plan. Additionally, the CSO was granted shares of the Company equaling 0.5% of the common shares of the Company on an issued and outstanding basis at the time of the effective date of the employment agreement, to be immediately vested.  On October 15, 2025, this represented a total of 87,861 common shares with a fair value of $2.00 per share or a total of $175,723. </span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>As at October 31, 2025, the Company recognized wages payable of $10,000 on the condensed balance sheets.</span></span></span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;text-align:justify;margin-left:27pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Director 7 </i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 23, 2025, the Company appointed a new director to the board of directors, Director 7. The agreement has an effective date of October 23, 2025, an indefinite term, and beginning November 2025, entitles the Director to quarterly compensation of $15,000.  On June 15, 2026, board members were issued a compensation notice, advising them of adjustments to their board compensation. All board members will be eligible for an annual cash compensation of $50,000; the chair of the board will receive an annual compensation of $100,000.  Additionally, on an annual basis, each board member will be granted the equivalent of $100,000 worth of Restricted Share Units, the number of shares will be determined based on the closing price on the grant date.  Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months.  The chairman of the board will receive the equivalent of $150,000 under the same terms as the other board members.  Eligibility will be determined on the "continuous service" conditions as defined in the board member's agreement.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Furthermore, all board members serving on any of the committees will receive the following; Nominating and Governance committee members will receive $5,000 per year, with the chair of the committee receiving $7,500; Compensation committee members will receive $6,000 per year, with the chair of the committee receiving $12,000 and, Audit committee members will receive $7,500 per year, with the chair of the committee receiving $15,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>During the three-and nine-months ending July 31, 2026, the total expense incurred in connection with the board agreement was $15,125 and $45,125, respectively, and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 28, 2025, a company to which Director 7 is related, subscribed to purchase 869,566 common shares of the Company at $2.30 per share for a total investment of $2,000,001.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On December 1, 2025, the Company entered into a consulting agreement with a company to which Director 7 is related. The agreement had a total contract amount of $100,000. Per the agreement, $25,000 was due up front, with monthly payments of $6,818 to be made through the remaining 11-month term of the agreement. During the three and nine months ended July 31, 2026, the Company expensed $25,000 and $66,667, respectively, in connection with this agreement and is included within consulting on the unaudited condensed interim statements of operations. As of July 31, 2026, $6,060 is included within prepaid expenses on the unaudited condensed balance sheet.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In January 2026, a company to which Director 7 is related subscribed to purchase 352,174 common shares of the Company at $2.30 per share for a total investment of $810,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In March 2026, a company to which Director 7 is related subscribed to purchase 262,500 common shares of the Company at $4.00 per share for a total investment of $1,050,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On May 12, 2026, a company to which Director 7 is related exercised 422,500 warrants under the warrant incentive Program at an exercise price of $0.80 for gross proceeds of $338,000.  The Company issued 422,500 common shares, along with new warrants totaling 422,500 purchased at $0.001 for gross proceeds of $422.  The new warrants have an exercise price of $2.30, with a three-year expiry date from the date of issuance.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On June 18, 2026, a company to which Director 7 is related exercised 202,500 warrants under the warrant incentive Program at an exercise price of $0.80 for gross proceeds of $162,000.  The Company issued 202,500 common shares, along with new warrants totaling 202,500 purchased at $0.001 for gross proceeds of $202.  The new warrants have an exercise price of $2.30, with a three-year expiry date from the date of issuance.</span></span></span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;text-align:justify;margin-left:27pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Director 8 </i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Effective November 1, 2025, the Company appointed a new director to the board of directors, Director 8. The agreement has an effective date of October 31, 2025, an indefinite term, and beginning November 2025, entitles the Director to quarterly compensation of $15,000. On June 15, 2026, board members were issued a compensation notice, advising them of adjustments to their board compensation. All board members will be eligible for an annual cash compensation of $50,000; the chair of the board will receive an annual compensation of $100,000.  Additionally, on an annual basis, each board member will be granted the equivalent of $100,000 worth of Restricted Share Units, the number of shares will be determined based on the closing price on the grant date.  Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months.  The chairman of the board will receive the equivalent of $150,000 under the same terms as the other board members.  Eligibility will be determined on the "continuous service" conditions as defined in the board member's agreement.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Furthermore, all board members serving on any of the committees will receive the following; Nominating and Governance committee members will receive $5,000 per year, with the chair of the committee receiving $7,500; Compensation committee members will receive $6,000 per year, with the chair of the committee receiving $12,000 and, Audit committee members will receive $7,500 per year, with the chair of the committee receiving $15,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>During the three-and nine-months ending July 31, 2026, the total expense incurred in connection with this agreement was $15,625 and $45,625 respectively.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;text-align:justify;margin-left:27.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>In November 2025, a company controlled by Director 8 subscribed to purchase 10,869 common shares of the Company at $2.30 per share for a total investment of $24,999.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Director 9 </i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On June 15, 2026, Director 9 was appointed to the Company's board of directors.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>All board members will be eligible for an annual cash compensation of $50,000; the chair of the board will receive an annual compensation of $100,000.  Additionally, on an annual basis, each board member will be granted the equivalent of $100,000 worth of Restricted Share Units, the number of shares will be determined based on the closing price on the grant date.  Twenty-five percent (25%) of the shares will vest every 3 months for the following twelve months.  The chairman of the board will receive the equivalent of $150,000 under the same terms as the other board members.  Eligibility will be determined on the "continuous service" conditions as defined in the board member's agreement.  Furthermore, all board members serving on any of the committees will receive the following; Nominating and Governance committee members will receive $5,000 per year, with the chair of the committee receiving $7,500; Compensation committee members will receive $6,000 per year, with the chair of the committee receiving $12,000 and, Audit committee members will receive $7,500 per year, with the chair of the committee receiving $15,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>During the three-and nine-months ending July 31, 2026, the total expense incurred in connection with this agreement was $8,750 and $8,750 respectively.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Director 10</i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On June 15, 2026, Director 10 was appointed to the Company's board of directors.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>All board members will be eligible for an annual cash compensation of $50,000; the chair of the board will receive an annual compensation of $100,000.  Additionally, on an annual basis, each board member will be granted the equivalent of $100,000 worth of Restricted Share Units, the number of shares will be determined based on the closing price on the grant date.  Twenty-five percent (25%) of the shares will vest every 3 months for the following twelve months.  The chairman of the board will receive the equivalent of $150,000 under the same terms as the other board members.  Eligibility will be determined on the "continuous service" conditions as defined in the board member's agreement.  Furthermore, all board members serving on any of the committees will receive the following; Nominating and Governance committee members will receive $5,000 per year, with the chair of the committee receiving $7,500; Compensation committee members will receive $6,000 per year, with the chair of the committee receiving $12,000 and, Audit committee members will receive $7,500 per year, with the chair of the committee receiving $15,000.</span></span></span></span></span></span></p> <div style="font-family:Times New Roman"></div> <p style="font-family:Times New Roman;margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>During the three-and nine-months ending July 31, 2026, the total expense incurred in connection with this agreement was $7,938 and $7,938 respectively.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Director 11</i></span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On June 15, 2026, Director 11 was appointed to the Company's board of directors.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>All board members will be eligible for an annual cash compensation of $50,000; the chair of the board will receive an annual compensation of $100,000. Additionally, on an annual basis, each board member will be granted the equivalent of $100,000 worth of Restricted Share Units, the number of shares will be determined based on the closing price on the grant date.  Twenty-five percent (25%) of the shares will vest every 3 months for the following twelve months.  The chairman of the board will receive the equivalent of $150,000 under the same terms as the other board members.  Eligibility will be determined on the "continuous service" conditions as defined in the board member's agreement.  Furthermore, all board members serving on any of the committees will receive the following; Nominating and Governance committee members will receive $5,000 per year, with the chair of the committee receiving $7,500; Compensation committee members will receive $6,000 per year, with the chair of the committee receiving $12,000 and, Audit committee members will receive $7,500 per year, with the chair of the committee receiving $15,000.</span></span></span></span></span></span></p> <p style="font-family:Times New Roman;margin-left:27pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the three- and nine-months ending July 31, 2026, the total expense incurred in connection with this agreement was $8,688 and $8,688 respectively.</span></span></p> <p style="font-family:Times New Roman;margin-left:27pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Head of Strategy and Transformation</i></span></span></p> <p style="font-family:Times New Roman;margin-left:27pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 17, 2025, the Company entered into a consulting agreement with a company controlled by an individual who was appointed Head of Strategy and Transformation on February 9, 2026. During the three and nine months ended July 31, 2026, the Company incurred consulting fees of $55,369 and $96,574, respectively, under this arrangement. As part of this appointment, the Company granted 50,000 stock options with an exercise price of $2.30, an expiry term of 5 years from the grant date of February 9, 2026, and a fair value of $75,500.  Twenty five percent of the options vest every three months from the grant date.  For the three- and nine-months ending July 31, 2026, the Company recognized under consulting fees on the unaudited condensed interim statements of operations related to the value of the options granted and now vested, $19,030 and $35,578, respectively.  As of July 31, 2026, $10,594 remained payable to the related party and was included in accounts payable and accrued liabilities - related party in the unaudited condensed interim balance sheet.</span></span></p> <p style="font-family:Times New Roman;margin-left:27pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Head of Business Development and Licensing</i></span></span></p> <p style="font-family:Times New Roman;margin-left:27pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 5, 2026, the Company entered into a consulting agreement with a company controlled by an individual who was appointed Head of Business Development and Licensing on March 2, 2026. During the three and nine months ended July 31, 2026, the Company incurred consulting fees of $37,500 and $62,500, respectively, under this arrangement. As of July 31, 2026, $12,500 remained payable to the related party and was included in accounts payable and accrued liabilities - related party in the unaudited condensed interim balance sheet.</span></span></p> </div> </div> 3722 3722 7500 10000 82500 82500 66000 0.8 26686 92686 25000 113500 10000 1000000 0.001 250000 99778 99778 99778 250000 99782 99782 99782 250000 80000000 99783 99783 99783 250000 99782 11745 34852 50000 50000 400000 400 400000 250000 250 250000 7500 10000 9900 0 30000 19800 80000 45000 15000 30000 90000 1000000 0.001 250000 99778 99778 99778 250000 99782 99782 99782 250000 80000000 99783 99783 99783 250000 99782 11745 34852 270000 0.0075 37500 20000000 150000000 If the financing completed is a minimum of $15 million at a minimum of $150 million pre-money market capitalization, then then two-thirds of the $37,500 or $24,750 will be earned and paid out. 12500 37500 0 212500 0 100000 20000 0 2000000 0.001 500000 199555 199555 199555 500000 199563 199563 199563 500000 80000000 199566 199566 199566 500000 199563 23490 69703 15000 50000 100000 100000 Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months. 150000 5000 7500 6000 12000 7500 15000 20000 50000 500000 500 500000 500000 500 500000 10000 30000 40000 100000 0.4 57527 28936 38052 240000 20000 35000 3000 0.005 87861 2 175723 45000 15000 50000 100000 100000 Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months. 150000 5000 7500 6000 12000 7500 15000 15125 45125 7500 9900 0.025 5000000 29700 89100 14850 19434 2.3 11175 4 22350 300000 25000 2000 0.025 439306 878612 0.005 87861 0.005 87861 92253 289796 413094 15000 1500 4000 0 12500 0 28500 2280 0 10875 13594 640 10235 216000 18000 0.0025 43931 2 87861 6000 10000 50000 0.4 18553 2033 11233 2643 240000 20000 0.005 87861 2 175723 10000 15000 50000 100000 100000 Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months. 150000 5000 7500 6000 12000 7500 15000 15125 45125 869566 2.3 2000001 100000 25000 6818 25000 66667 6060 352174 2.3 810000 262500 4 1050000 422500 0.8 338000 422500 422500 0.001 422 2.3 202500 0.8 162000 202500 202500 0.001 202 2.3 15000 50000 100000 100000 Twenty five percent (25%) of the shares will vest every 3 months for the following twelve months. 150000 5000 7500 6000 12000 7500 15000 15625 45625 10869 2.3 24999 50000 100000 100000 Twenty-five percent (25%) of the shares will vest every 3 months for the following twelve months. 150000 5000 7500 6000 12000 7500 15000 8750 8750 50000 100000 100000 Twenty-five percent (25%) of the shares will vest every 3 months for the following twelve months. 150000 5000 7500 6000 12000 7500 15000 7938 7938 50000 100000 100000 Twenty-five percent (25%) of the shares will vest every 3 months for the following twelve months. 150000 5000 7500 6000 12000 7500 15000 8688 8688 55369 96574 50000 2.3 75500 19030 35578 10594 37500 62500 12500 <div> <p style="text-align:justify;margin-top:0pt;margin-bottom:10pt;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>11.<span style="display:inline-block;width:6.5pt"> </span></strong><strong>Share capital</strong></span></span></span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Write-off of Deferred Offering Costs</i></span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company was pursuing an Initial Public Offering "IPO", in which they were capitalizing costs incurred in connection with the potential offering as deferred offering costs. During the nine months ended July 31, 2026, the Company decided to pursue a direct listing rather than go forward with the IPO. Due to this, the Company wrote off $73,169 of deferred offering costs that were capitalized for the previously pursued IPO. These costs are recorded as a write-off of offering costs on the unaudited interim condensed statements of operations during the three and nine months ended July 31, 2026.</span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Private Placements - Non-brokered</i></span></span></span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company closed several non-brokered private placements in December 2024 and January 2025. The private placements consisted of units which were comprised of 1 share of common stock and 1 warrant. The warrants vested immediately, have a two-year life, and an exercise price equal to the price of the unit in the private placement. The price of the units of the private placements was $0.80. The Company issued a total of 687,500 shares for total proceeds of $550,000.</span></span></span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company closed a non-brokered private placement in May 2025. The private placement consisted of units which were comprised of 1 share of common stock and 1 warrant. The warrants vested immediately, have a two-year life, and an exercise price equal to the price of the unit in the private placement. The price of the units of the private placements was $0.40. The Company issued a total of 3,750,000 shares for total proceeds of $1,500,000.  During the year ended October 31, 2025, in connection with the private placements the Company incurred costs of $31,587.</span></span></span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 23, 2025, the Company received board approval, to open a non-brokered private placement of up to $10,000,000, offering shares at a price of $2.30 per share.  On October 28, 2025, the Company closed the first tranche and issued 891,306 shares for total proceeds of $2,050,004.  During this private placement, the Company issued 869,566 shares for total proceeds of $2,000,002, to a company to which a member of the board of directors is related.</span></span></span></span></p> <p style="text-align:justify;margin-left:28.8pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On November 12, 2025, the Company closed the second tranche of the non-brokered private placement and issued 87,956 shares for total proceeds of $202,299. The Company incurred $7,000 of offering costs in connection with this non-brokered private placement. During this private placement, the Company issued 10,869 common shares of the Company at $4.00 per share for a total investment of $24,999 to a company to which a member of the board of directors is related</span></span></span></span></p> <div></div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On January 26, 2026, the Company closed the third and final tranche of the non-brokered private placement and issued 352,174 shares for total proceeds of $810,000 to a company to which a member of the board of directors is related</span></span></span></span></p> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On January 20, 2026, the Company received board approval, to open a non-brokered private placement of up to $5,000,000, offering shares at a price of $4.00 per share.  On March 23, 2026, the Company closed the non-brokered private placement and issued 486,970 shares at a price of $4.00 per share for total proceeds of $1,947,880.  The Company incurred $9,828 of offering costs in connection with this non-brokered private placement.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Private Placements - Brokered</i></span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On July 31, 2025, the Company filed with the Securities and Exchange Commission ("SEC") a Regulation Crowdfunding ("Reg CF") to raise up to $5,000,000 at a price of $2.00 per common share of the Company.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On September 2, 2025, the first tranche of the raise was closed with total gross proceeds of $2,726,303, representing a commitment of the Company to issue 1,363,151 common shares.  After associated fees and costs of $278,364, the net amount of $2,447,938 was advanced to the Company.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On September 18, 2025, a second tranche of the raise was closed with total gross proceeds of $1,969,970, representing a commitment of the Company to issue 984,985 common shares.  After associated fees and costs of $200,100, the net amount of $1,769,860 was advanced to the Company.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 7, 2025, the third and final tranche of the raise was closed with total gross proceeds of $303,652, representing a commitment of the Company to issue 151,826 common shares.  After associated fees and costs of $31,299, the net amount of $272,353 was advanced to the Company.  With the close of this final tranche, the Company issued a total of 2,499,962 common shares with total gross proceeds equaling $4,999,925 less total issuance costs of $509,773 for a net amount received of $4,490,152.</span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In connection with these raises the Company also issued 49,999 shares of common stock to the broker with a fair value of $99,998.</span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The fair value of the warrants issued in the private placements during the nine months ended July 31, 2026, and the year ended October 31, 2025, was determined using the following Black-Scholes Pricing model assumptions:</span></span></span></span></p> </div> <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:80%"> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:justify;white-space:nowrap"> </td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">July 31, 2026</span></p> </td> <td style="border-top:1.5pt solid black;padding-left:33pt"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">October 31, 2025</span></p> </td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.80</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $0.80</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20260910190049912">-</span></span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.00 - 3.00 years</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>102.64% to 122.96%</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.69% - 4.31%</span></span></span></span></td> </tr> </table> </div> </div> <div> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Shares Issued for Services </i></span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 8, 2025, the Company entered into a service agreement in which it was agreed that the consultant would provide advisory and consultancy services related to the Company's Form C disclosure documents required for a planned Regulation Crowdfunding ("Reg CF") offering, advising the Company on marketing, organizational and financial issues and business development.  The agreement was for a twelve (12) month period from its effective date of May 8, 2025, and includes a one-time cash payment of $75,000 as a retainer to be expensed monthly over the term of the agreement and is included in the consulting expense on the unaudited condensed interim statements of operations.  As of October 31, 2025, a balance of $37,500 remained outstanding and was included in the prepaid expenses on the condensed balance sheets. In addition to performing the defined services, the vendor was to make a one-time purchase of 1,200,000 shares of the Company's common stock at a price of $0.001 per share for gross proceeds of $1,200 which is accounted for as a reduction of the fair value of the shares issued.  The fair value of the shares was determined to be $480,000, which, net of the $1,200, is to be expensed over the term of the agreement. As of October 31, 2025, $247,927 was included in prepaid expenses on the condensed balance sheet.  During the three and nine months ended July 31, 2026, a total of $9,206 and $247,926, respectively, was expensed as consulting fees on the unaudited condensed interim statements of operations. </span></span>During the three and nine months ended July 31, 2025, a total of $110,190 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.</span></span></p> </div> <div></div> <div> <p style="margin-left:27pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 27, 2025, the Company granted 150,000 Restricted Share Units ("RSUs") to an advisor, having a fair value of $121,091.  The RSUs vested immediately and were expensed as consulting expense.  The RSUs may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated, other than under specific circumstances as defined in the Restricted Share Unit Awards Agreement.</span></span></span></span></p> </div> <div> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On January 15, 2025, Director 1 received 82,500 shares of common stock for a fair value of $66,000 as disclosed in Note 10 - Related Party Transactions.  The stock vested immediately and $66,000 was expensed and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In May 2025, the Company also issued 416,667 shares of common stock to a consultant for a fair value of $166,667, which was expensed over the 24-month term of the agreement. As of October 31, 2025, $126,484 is included in prepaid expenses in the condensed balance sheets. On May 27, 2026, the Company mutually agreed to terminate, without penalty this consulting agreement and therefore during the three and nine months ended July 31, 2026, a total of $84,931 and $126,484 was expensed as consulting fees on the unaudited condensed interim statements of operations. During the three and nine months ended July 31, 2025, a total of $19,178, was recognized and was expensed as consulting fees on the unaudited condensed interim statements of operations. As of July 31, 2026, there was no longer any prepaid balance to be expensed.</span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 15, 2025, the Company also issued 442,514 shares of common stock to employees and a director of the Company as part of their employment and board of director's agreements with a fair value of $885,028.  The terms of these agreements were indefinite and the shares vested immediately.</span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On March 17, 2026, the Company issued 19,434 shares at a price of $2.30 per share to a director in settlement of $44,698 in fees owed related to their consulting and director's agreements. The fair value of the shares was $44,698.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On April 28, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will assist in video hosting, and distribution services for marketing and communications activities. In connection with the agreement, the Company is to issue the vendor a total of 10,002 common shares in six separate issuances of 1,667 shares each, with the issuance dates being the 28^th day commencing in May 2026 until October 2026. The fair value of the shares issued at May 28, 2026, June 28, 2026, and July 28, 2026, were $22,905, $18,270, and $12,986, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $54,161 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <div style="margin-top:13.3333px;margin-bottom:13.3333px"></div> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 14, 2026, the Company issued 11,175 shares at a price of $4.00 per share to a director in settlement of $44,700 in fees owed related to their consulting and director's agreements. The fair value of the shares was $44,700.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will advise the Company regarding media creation, online awareness strategies, and introductions to relevant business contacts and appropriate strategic partners. In connection with the agreement, the Company is to issue the vendor a total of 210,000 common shares in three separate issuances of 70,000 shares each, with the issuance dates being May 22, 2026, June 22, 2026, and July 22, 2026. The fair value of the shares issued at these dates were $945,000, $852,600, and $653,800, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $2,451,400 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will provide strategic marketing and communications services designed to increase awareness, visibility, and engagement with respect to the Company's business, initiatives, and overall market presence. In connection with the agreement, the Company is to issue the vendor a total of 30,000 common shares in six separate issuances of 5,000 shares each, issuance dates being the 21^st day of each month commencing in June 2026 until November 2026. The fair value of the shares issued at June 21, 2026, and July 21, 2026, were $66,400 and $46,700, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $113,100 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will provide corporate advisory and investor relations services. In connection with the agreement, the Company is to issue the vendor a total of 9,000 common shares in six separate issuances of 1,500 shares each, issuance dates being the 21^st day of each month commencing in June 2026 until November 2026. The fair value of the shares issued at June 21, 2026, and July 21, 2026, were $19,920 and $14,010, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $33,930 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <div style="margin-top:13.3333px;margin-bottom:13.3333px"></div> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 21, 2026. the Company entered into a marketing agreement with a vendor. Under the terms of the agreement, the vendor will provide digital media and brand awareness, social media management, content creation, and distribution services. In connection with the agreement, the Company is to issue the vendor a total of 30,000 common shares in two separate issuances of 15,000 shares each, with the issuance dates being June 21, 2026, and July 21, 2026. The fair value of the shares issued at June 21, 2026, and July 21, 2026, were $199,200 and $140,010, respectively, with the fair value per share being determined based off the closing price of the shares at the date of issuance, as the issuance of the shares was contingent upon a service condition leading up to the issuance date. During the three and nine months ended July 31, 2026, a total of $339,210 was recognized and expensed as consulting fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Shares Issued for Conversion of Payables</i></span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Between November 30, 2024 and January 31, 2025, the Company issued 207,594 shares of common stock with a fair value of $122,898 to settle outstanding payables. These transactions resulted in a gain on conversion of payables of $43,176.</span></span></span></span></p> </div> <div> <p style="margin-left:28.1pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Warrants</strong></span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Warrants Issued for Services</i></span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On January 21, 2025, the Company issued 82,500 warrants to Director 1 for a fair value of $26,686. The warrants vested immediately. During the three- and nine-months ending July 31, 2025, an expense of $26,686 was incurred and was included within management and directors' salaries and fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 5, 2025, the Company granted milestone warrants to three Directors.  The milestones were defined as follows:</span></span></span></span></p> <p style="text-align:justify;margin-left:45.8pt;margin-bottom:0pt;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Milestone 1</strong> - One quarter of the warrants granted Warrants shall vest upon the Company completing and receiving the results of the three-month Collagen Study in Boston, MA.  Milestone achieved July 8, 2025.</span></span></span></span></p> <p style="text-align:justify;margin-left:45.8pt;margin-bottom:0pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Milestone 2</strong> - Second quarter of the warrants granted shall vest upon the Company listing its shares of common stock in The Nasdaq Stock Market, LLC, or any such other recognized stock exchange in North America.  Milestone achieved May 21, 2026.</span></span></span></span></p> <p style="text-align:justify;margin-left:45.8pt;margin-bottom:0pt;margin-top:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Milestone 3</strong> - Third quarter of the warrants granted shall vest upon the Company's listed shares of common stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater in the currency of the recognized stock exchange in North America on which the shares of common stock are listed. Milestone achieved June 17, 2026.</span></span></span></span></p> <p style="text-align:justify;margin-left:45.8pt;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Milestone 4</strong> - Fourth and final quarter if the warrants granted shall vest upon the Company submitting a 510(k) application to the FDA.</span></span></span></span></p> </div> <div></div> <div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On July 8, 2025, the first milestone was achieved, and the Company recorded a total expense of $399,111 within management and directors' salaries and fees on the unaudited condensed interim statements of operations during the year ended October 31, 2025.</span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 21, 2026, the second milestone was achieved, and the Company recorded a total expense of $399,127 within management and directors' salaries and fees on the unaudited condensed interim statements of operations during the three months ending July 31, 2026.</span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 17, 2026, the third milestone was achieved, and the Company recorded a total expense of $399,132 within management and directors' salaries and fees on the unaudited condensed interim statements of operations during the three months ending July 31, 2026.</span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>For </span></span>the fourth milestone, the Company assessed a greater than 70% probability that this would occur. As of October 31, 2025, the Company anticipated that this would occur on June 30, 2026. As of July 31, 2026, the Company anticipates that this will now occur on March 31, 2027. The expense for the three and nine months ended July 31, 2026, was $46,979 and $139,406, respectively, and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations. During the three and nine months ended July 31, 2025, an expense of $57,309 and is included within management and directors' salaries and fees on the unaudited condensed interim statements of operations. See Note 10 - Related Party Transactions for details.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In May 2025, the Company issued 416,667 warrants with a fair value of $102,912 to a consultant for a 24-month consulting agreement. As of October 31, 2025, $78,100 was reported as a prepaid expense on the condensed balance sheet. On May 27, 2026, the Company mutually agreed to terminate, without penalty, the consulting agreement with the consultant, the early termination of this agreement accelerated the prepaid expense of $78,100 in non-cash stock-based compensation to be fully expensed as on the date of the termination. During the three and nine months ended July 31, 2026, a total of $52,445 and $78,100, respectively, was expensed as consulting fees on the unaudited condensed interim statements of operations. During the three and nine months ended July 31, 2025, a total of $11,842, was expensed as consulting fees on the unaudited condensed interim statements of operations.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On December 23, 2025, a Director of the Company, exercised 500,000 milestone warrants for a total amount of proceeds of $500.  The Company issued 500,000 common shares in connection with the warrant exercise.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 22, 2026, a Director of the Company, exercised 500,000 milestone warrants for a total amount of proceeds of $500.  The Company issued 500,000 common shares in connection with the warrant exercise.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 22, 2026, a former Director of the Company, exercised 400,000 milestone warrants for a total amount of proceeds of $400.  The Company issued 400,000 common shares in connection with the warrant exercise.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 8, 2026, a shareholder of the Company, to whom milestone warrants had been transferred, exercised 100,000 milestone warrants for a total amount of proceeds of $100.  The Company issued 100,000 common shares in connection with the warrant exercise.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 18, 2026, a former Director of the Company, exercised 250,000 milestone warrants for a total amount of proceeds of $250.  The Company issued 250,000 common shares in connection with the warrant exercise.</span></span></span></span></p> <p style="margin-left:28.35pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The fair value of the warrants issued as compensation during the nine months ended July 31, 2026, and the year ended October 31, 2025, was determined using the following Black-Scholes Pricing model assumptions:</span></span></span></span></p> </div> <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:80%"> <tr> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap"> </td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>July 31, 2026</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October 31, 2025</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $0.80</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.001 - $0.80</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20260613022753005">-</span></span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.00 - 3.15 years</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>105.57% to 139.13%</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:1.5pt solid #000000;background-color:#e6efff;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:1.5pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:1.5pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.90% - 4.19%</span></span></span></span></td> </tr> </table> </div> </div> <p style="margin:0pt"> </p> <div></div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The stock price in the model was based on the methodology disclosed in Note 3, the volatility was based on the historical volatility of comparable public companies, and the expected term is determined using the Simplified Method.</span></span></span></span></p> <div> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Warrant Incentive Program</i></span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On October 1, 2025, the Board of Directors approved a Warrant Exercise Incentive Program (the "Incentive Program"), inviting current warrant holders to exercise their warrants early at the existing exercise price and if they choose to do so, they are then entitled to subscribe for a new full warrant for each warrant exercised, with a purchase price of $0.001, a 36-month expiry date and an exercise price of $2.30.  The initial expiry date of the Incentive Program was December 31, 2025, however, on December 15, 2025, the Board agreed to extend the expiry date of the Incentive Program to April 30, 2026.  On April 28, 2026, the Board agreed to amend an extend further the expiry date of the Incentive Program to June 30, 2026.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On February 11, 2026, under the Company Incentive Program, an initial group of warrant holders exercised 563,573 warrants for a total amount of proceeds of $427,928 and purchased 563,573 new warrants at $0.001 for an additional $564 for the new warrants.  The fair value of the new warrants was calculated as $692,534.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 12, 2026, under the Company Incentive Program, a group of warrant holders exercised 4,342,648 warrants for a total amount of proceeds of $1,963,967 and purchased 4,342,648 new warrants at $0.001 for an additional $4,343 for the new warrants.  Of the total warrants exercised, 422,500 warrants were exercised by a company to which one of the Directors of the Company is related and is reported in Note 10 - Related Party Transactions. The fair value of the new warrants was calculated as $11,599,167.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 5, 2026, under the Company Incentive Program, a warrant holder exercised 416,667 warrants for a total amount of proceeds of $166,667 and purchased 416,667 new warrants at $0.001 for an additional $417 for the new warrants.  The fair value of the new warrants was calculated as $5,597,073.</span></span></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 18, 2026, under the Company Incentive Program, a warrant holder exercised 202,500 warrants for a total amount of proceeds of $162,000 and purchased 202,500 new warrants at $0.001 for an additional $202 for the new warrants.  The warrant holder is company to which a Director of the Company is related and is reported in Note 10 - Related Party Transactions. The fair value of the new warrants was calculated as $2,328,266.</span></span></span></span></p> <p style="margin-left:28.35pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The fair value of the warrants issued under the incentive program during the nine months ended July 31, 2026, was determined using the following Black-Scholes Pricing model assumptions:</span></span></span></span></p> </div> <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:65%"> <tr> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap"> </td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>July 31, 2026</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30- $15.25</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.0 years</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>79.42% - 80%</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:1.5pt solid #000000;background-color:#e6efff;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:1.5pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.5% - 4.21%</span></span></span></span></td> </tr> </table> </div> </div> <div> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The share price in the model was based on pre-May 21, 2026, the most recent private placement price and post-May 21, 2026, the quoted price in the market, the volatility was based on the historical volatility of comparable public companies, and the expected term is determined using the Simplified Method.</span></span></span></span></p> <div></div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A summary of common stock warrant activity during the nine months ending July 31, 2026, and the year ending October 31, 2025, is as follows:</span></span></span></span></p> </div> <div> <div style="margin-left:0pt"> <div> <div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:justify;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong> </strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of</strong><br/><strong>Warrants</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted</strong><br/><strong>Average </strong><br/><strong>exercise </strong><br/><strong>price</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted</strong><br/><strong>Average</strong><br/><strong>remaining</strong><br/><strong>contractual life</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Aggregate</strong><br/><strong>intrinsic </strong><br/><strong>value</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at November 1, 2024</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">796,559</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.75</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20260613032735907_18">-</span></span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,936,667</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.26</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled/Forfeited</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid #000000;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at October 31, 2025</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.30</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.12</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">19,505,021</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,525,388</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.30</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,275,388</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.37</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled/Forfeited</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at July 31, 2026</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,983,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.61</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.00</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53,472,883</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at July 31, 2026</strong></span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,983,226</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.84</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.88</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45,163,883</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> </table> </div> </div> </div> </div> </div> <div> <p style="margin-left:28pt;text-indent:0.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of July 31, 2026, there remained an unrecognized stock-based compensation expense for the unvested warrants of $108,257.</span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Options</strong></span></span></span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On June 7, 2025, the Company approved a Stock Incentive Plan (the "Plan") and Stock-Based Compensation Agreement.  The Plan allows for a maximum of 3,000,000 common shares to be granted under the Plan.</span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><i>Options Issued for Services</i></span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On November 1, 2025, a total of 10,000 stock options were granted to an employee with a total fair value of $17,090, the options will vest 12 months from the grant date, the exercise price is $2.30 per share and will expire on November 1, 2030.  For the three and nine months ended July 31, 2026, the Company recognized under Management and directors' salaries and fees - related parties on the unaudited condensed interim statements of operations related to the value of the options granted and now vested, $4,273 and $12,818, respectively.</span></span></span></span></p> <p style="margin-left:27.95pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On February 9, 2026, a total of 200,000 stock options were granted, in allotments of 50,000 each, to a consultant and three advisors with a total fair value of $302,000.  Twenty-five percent of the options will vest every three months, the exercise price is $2.30 per share, and the expiration date is February 9, 2031.  For the three- and nine-months ending July 31, 2026, the Company recognized under </span></span>consulting <span><span>fees on the unaudited condensed interim statements of operations related to the value of the options granted and now vested, $76,121 and $142,312, respectively.</span></span></span></span></span></span></p> </div> <div></div> <div> <p style="text-align:justify;margin-left:28pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The fair value of the stock options during the nine months ended July 31, 2026, and the year ended October 31, 2025, was determined using the following weighted average Black-Scholes Option Pricing model assumptions:</span></span></span></span></p> </div> <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:80%"> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap;text-align:center"> </td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap;text-align:center"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>July 31, 2026</strong></span></p> </td> <td style="border-top:1.5pt solid black"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>October 31, 2025</strong></span></p> </td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $1.01</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $0.80</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.00 years</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.50 - 3.00 years</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>79.40% - 129.44%</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>124.45% - 170.85%</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.50% - 3.56%</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.72% - 4.23%</span></span></span></span></td> </tr> </table> </div> </div> <div> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The stock price in the model was based on the methodology disclosed in Note 3, the volatility was based on the historical volatility of comparable public companies, and the expected term is determined using the Simplified Method.</span></span></span></span></p> <p style="margin-left:28.8pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>A summary of common stock options activity during the nine months ended July 31, 2026, and the year ended October 31, 2025, is as follows.</span></span></span></span></p> </div> <div> <div style="margin-left:0pt"> <div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;white-space:nowrap"><strong> </strong></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of </strong><br/><strong>options</strong></span></span></span></span></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"> </td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted </strong><br/><strong>Average </strong><br/><strong>exercise price</strong></span></span></span></span></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"> </td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted </strong><br/><strong>Average </strong><br/><strong>remaining</strong><br/><strong>contractual </strong><br/><strong>life</strong></span></span></span></span></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"> </td> <td style="vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Aggregate </strong><br/><strong>intrinsic value</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, November 1, 2024</strong></span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="-sec-ix-hidden:Fxbrl_20260613055934189">-</span></strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">675,000</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.61</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.22</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled or forfeited</span></span></td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, October 31, 2025</strong></span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">675,000</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.61</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.22</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,142,500</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">210,000</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$2.30</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.48</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled or forfeited</span></span></td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">150,000</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.80</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, July 31, 2026</strong></span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">735,000</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$1.05</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.63</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,334,850</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable, July 31, 2026</strong></span></span></td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">575,000</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.87</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.44</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,278,250</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> </tr> </table> </div> </div> </div> </div> <p style="margin:0pt"> </p> <div> <p style="text-align:justify;margin:0pt 0pt 0pt 28pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>As of July 31, 2026, there remained an unrecognized stock-based compensation expense for the unvested options of $163,995.</span></span></span></span></p> </div> </div> 73169 0.8 687500 550000 0.4 3750000 1500000 31587 10000000 2.3 891306 2050004 869566 2000002 87956 202299 7000 10869 4 24999 352174 810000 5000000 4 486970 4 1947880 9828 5000000 2 2726303 1363151 278364 2447938 1969970 984985 200100 1769860 303652 151826 31299 272353 2499962 4999925 509773 4490152 49999 99998 <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:80%"> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:justify;white-space:nowrap"> </td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">July 31, 2026</span></p> </td> <td style="border-top:1.5pt solid black;padding-left:33pt"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">October 31, 2025</span></p> </td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.80</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $0.80</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20260910190049912">-</span></span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2.00 - 3.00 years</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>102.64% to 122.96%</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:33.35pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.69% - 4.31%</span></span></span></span></td> </tr> </table> </div> </div> 0 0.8 0 0.4 0.8 P2Y P3Y 0 1.0264 1.2296 0 0.0369 0.0431 75000 37500 1200000 0.001 1200 480000 1200 247927 9206 247926 110190 110190 150000 121091 82500 66000 66000 416667 166667 126484 84931 126484 19178 442514 885028 19434 2.3 44698 44698 10002 1667 22905 18270 12986 54161 54161 11175 4 44700 44700 210000 70000 945000 852600 653800 2451400 2451400 30000 5000 66400 46700 113100 113100 9000 1500 19920 14010 33930 33930 30000 15000 199200 140010 339210 339210 207594 122898 43176 82500 26686 26686 26686 80000000 399111 399127 399132 46979 139406 57309 57309 416667 102912 78100 78100 52445 78100 11842 11842 500000 500 500000 500000 500 500000 400000 400 400000 100000 100 100000 250000 250 250000 <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:80%"> <tr> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap"> </td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>July 31, 2026</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>October 31, 2025</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $0.80</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.001 - $0.80</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20260613022753005">-</span></span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1.00 - 3.15 years</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>105.57% to 139.13%</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:1.5pt solid #000000;background-color:#e6efff;width:33%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:1.5pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></td> <td style="width:33%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:1.5pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.90% - 4.19%</span></span></span></span></td> </tr> </table> </div> </div> 0 0.4 0.8 0 0.001 0.8 P1Y P3Y1M24D 0 1.0557 1.3913 0 0.039 0.0419 0.001 2.3 563573 427928 563573 0.001 564 692534 4342648 1963967 4342648 0.001 4343 422500 11599167 416667 166667 416667 0.001 417 5597073 202500 162000 202500 0.001 202 2328266 <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:65%"> <tr> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap"> </td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>July 31, 2026</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-top:0.75pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30- $15.25</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;background-color:#e6efff;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.0 years</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>79.42% - 80%</span></span></span></span></td> </tr> <tr> <td style="margin-top:0pt;margin-bottom:0pt;border-bottom:1.5pt solid #000000;background-color:#e6efff;width:50%;padding-left:5pt;padding-right:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:50%;padding-right:5pt;padding-left:5pt;vertical-align:top;border-bottom:1.5pt solid #000000;text-align:center;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.5% - 4.21%</span></span></span></span></td> </tr> </table> </div> </div> 2.3 15.25 2.3 P3Y 0.7942 0.80 0.035 0.0421 <div> <div style="margin-left:0pt"> <div> <div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt;border-color:#000000"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:justify;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong> </strong></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of</strong><br/><strong>Warrants</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted</strong><br/><strong>Average </strong><br/><strong>exercise </strong><br/><strong>price</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted</strong><br/><strong>Average</strong><br/><strong>remaining</strong><br/><strong>contractual life</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Aggregate</strong><br/><strong>intrinsic </strong><br/><strong>value</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at November 1, 2024</strong></span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">796,559</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.75</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20260613032735907_18">-</span></span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8,936,667</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.26</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled/Forfeited</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid #000000;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at October 31, 2025</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,733,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.30</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.12</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">19,505,021</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,525,388</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.30</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,275,388</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.37</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled/Forfeited</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;width:2%"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:justify;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding at July 31, 2026</strong></span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,983,226</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.61</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.00</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%;background-color:#e6efff"> </td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%;background-color:#e6efff"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">53,472,883</span></span></td> <td style="vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%;background-color:#e6efff"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable at July 31, 2026</strong></span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,983,226</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.84</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2.88</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:1%"> </td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:right;width:13%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">45,163,883</span></span></td> <td style="vertical-align:bottom;border-top:2.25pt double #000000;border-bottom:2.25pt double #000000;text-align:left;width:2%"> </td> </tr> </table> </div> </div> </div> </div> </div> 796559 0.75 0 8936667 0.26 0 0 0 0 9733226 0.3 P3Y1M13D 19505021 5525388 2.3 7275388 0.37 0 0 7983226 1.61 P3Y 53472883 6983226 1.84 P2Y10M17D 45163883 108257 3000000 10000 17090 2.3 4273 12818 200000 50000 302000 2.3 76121 142312 <div> <div> <table cellpadding="0" cellspacing="0" style="margin-right:auto;margin-left:auto;border-collapse:collapse;font-size:10pt;width:80%"> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap;text-align:center"> </td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;white-space:nowrap;text-align:center"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>July 31, 2026</strong></span></p> </td> <td style="border-top:1.5pt solid black"> <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>October 31, 2025</strong></span></p> </td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-top:0.75pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $1.01</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Exercise price</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$2.30</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$0.40 - $0.80</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Expected life</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5.00 years</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>0.50 - 3.00 years</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Volatility</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>79.40% - 129.44%</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>124.45% - 170.85%</span></span></span></span></td> </tr> <tr> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Risk-free interest Rate</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.50% - 3.56%</span></span></span></span></td> <td style="width:33%;padding-right:5.4pt;padding-left:5.4pt;vertical-align:top;border-bottom:1.5pt solid #000000;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3.72% - 4.23%</span></span></span></span></td> </tr> </table> </div> </div> 2.3 0.4 1.01 2.3 0.4 0.8 P5Y P0Y6M P3Y 0.794 1.2944 1.2445 1.7085 0.035 0.0356 0.0372 0.0423 <div> <div style="margin-left:0pt"> <div> <div> <table cellpadding="0" cellspacing="0" style="width:100%;border-collapse:collapse;font-size:10pt"> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:justify;white-space:nowrap"><strong> </strong></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Number of </strong><br/><strong>options</strong></span></span></span></span></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"> </td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted </strong><br/><strong>Average </strong><br/><strong>exercise price</strong></span></span></span></span></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"> </td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Weighted </strong><br/><strong>Average </strong><br/><strong>remaining</strong><br/><strong>contractual </strong><br/><strong>life</strong></span></span></span></span></td> <td style="vertical-align:middle;border-top:1.5pt solid rgb(0, 0, 0);border-bottom:0.75pt solid rgb(0, 0, 0);text-align:center;white-space:nowrap"> </td> <td style="vertical-align:middle;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>Aggregate </strong><br/><strong>intrinsic value</strong></span></span></span></span></td> <td style="vertical-align:bottom;border-top:1.5pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center;white-space:nowrap"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, November 1, 2024</strong></span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="-sec-ix-hidden:Fxbrl_20260613055934189">-</span></strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>-</strong></span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">675,000</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.61</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.22</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled or forfeited</span></span></td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, October 31, 2025</strong></span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">675,000</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.61</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.22</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,142,500</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Granted</span></span></td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">210,000</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$2.30</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4.48</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercised</span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled or forfeited</span></span></td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">150,000</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.80</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td> <td style="width:2%;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, July 31, 2026</strong></span></span></td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">735,000</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$1.05</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.63</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,334,850</span></span></td> <td style="width:2%;vertical-align:bottom;background-color:#e6efff;border-top:0.75pt solid #000000;border-bottom:0.75pt solid #000000;text-align:center"> </td> </tr> <tr> <td style="padding-right:5.4pt;padding-left:5.4pt;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable, July 31, 2026</strong></span></span></td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">575,000</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.87</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.44</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> <td style="width:10%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,278,250</span></span></td> <td style="width:2%;vertical-align:bottom;border-top:0.75pt solid #000000;border-bottom:2.25pt double #000000;text-align:center"> </td> </tr> </table> </div> </div> </div> </div> 0 0 0 675000 0.61 P3Y2M19D 0 0 0 0 675000 0.61 P3Y2M19D 1142500 210000 2.3 P4Y5M23D 0 0 150000 0.8 735000 1.05 P3Y7M17D 5334850 575000 0.87 P3Y5M8D 4278250 163995 <div> <p style="margin-left:9pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>12.</strong>   <strong>Subsequent Events</strong></span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 21, 2026, 160,338 warrants expired unexercised.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 24, 2026, the Company issued 6,500 common shares to two vendors as part of their service agreements.  The fair value of these shares was determined based on the Nasdaq closing price on August 21, 2026, of $8.89 per share.</span></span></p> <p style="margin-left:28.05pt;text-align:justify;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On August 24, 2026, the Company issued a total of 5,259 common shares to a director in settlement of liabilities owed for advisory and director fees.  The fair value of these shares was determined based on the either a historical value of $2.30 per share for 3,658 shares and a volume weighted average price between May 21, 2026, and June 15, 2026, of $13.96 per share for 1,601 shares.</span></span></span></p> <div></div> <p style="margin-left:28pt;text-align:justify;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On August 27, 2026, the Board of Directors agreed to amend and restate a service agreement previously approved on July 12, 2026, wherein a vendor will be issued common shares in the Company as part of a compensation package including cash and equity, the originally agreed aggregate amount of 50,000 shares shall be increased to an aggregate amount of 67,000 shares.  The value of the original 50,000 common shares will be based on the closing trading price of the Company's shares on the previously agreed schedule of August 31^st and September 30^th.  The additional new shares that will be issued along with the issuances on August 31^st and September 30^th, in equal amounts of 8,500 shares per issuance with a reserved price based on the market closing price on August 26, 2026, of $6.98 per share.</span></span></span></span></p> <p style="text-align:justify;margin-left:28.05pt;text-indent:0.75pt;margin-top:10pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On September 1, 2026, the Company issued 35,167 common shares to two vendors as part of their service agreements.  The fair value of these shares was determined based on the Nasdaq closing price on August 28, 2026, of $7.07 per share for 1,667 common shares and on August 31, 2026, of $7.18 per share for 33,500 common shares.</span></span></span></span></p> <p style="margin-left:28pt;text-align:justify;margin-top:10pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On September 4, 2026, the Company raised gross proceeds of $1,753,998 through the exercise of warrants by four holders at an exercise price of $2.30 per share. In connection with the exercises, the Company issued an aggregate of 762,608 shares of common stock. The proceeds will be used to support ongoing operations. The shares issued upon exercise are restricted securities and are subject to a six-month Rule 144 holding period.</span></span></p> </div> 160338 6500 8.89 5259 2.3 3658 13.96 1601 50000 67000 50000 8500 6.98 35167 7.07 1667 7.18 33500 1753998 2.3 762608 <span style="font-size:10pt;font-family:Times New Roman">During our fiscal quarter ended July 31, 2026, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.</span> directors or executive officers false false false false